An investigation into the reliability of the Addenbrooke’s Cognitive Examination-III (ACE-III) and clinical research portfolio by Thomson, Hollie
 
 
 
 
 
 
 
 
 
Thomson, Hollie (2020) An investigation into the reliability of the 
Addenbrooke’s Cognitive Examination-III (ACE-III) and clinical research 
portfolio. D Clin Psy thesis. 
 
 
https://theses.gla.ac.uk/81414/  
 
 
Copyright and moral rights for this work are retained by the author  
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge  
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author  
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author  
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses  
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
 
  
 
 
 
 
 
 
 
An Investigation into the Reliability of the Addenbrooke’s Cognitive 
Examination-III (ACE-III) 
 
and  
 
Clinical Research Portfolio 
 
 
 
 
 
Hollie Thomson 
 
BA (Hons), MSc 
 
 
 
 
 
 
 
 
 
 
 
Submitted in part fulfilment of the requirements for the Degree of Doctorate in Clinical 
Psychology (D.Clin.Psy)  
 
 
Institute of Health and Wellbeing 
College of Medical, Veterinary and Life Sciences 
University of Glasgow 
 
 
 
February 2020 
 
 
 
Acknowledgements 
 
 
I would firstly like to thank all of the NHS GG&C staff who kindly took the time to 
participate in my research, as well as all of the Psychologists and Team Leads within Older 
Adult Community Mental Health Teams who assisted with recruitment, without whom this 
project would not have been possible.    
 
A huge thank you to my research supervisor, Professor Jon Evans, for his invaluable help, 
reassurance, and guidance throughout.  Thanks also to my field supervisor, Dr Stephanie 
Crawford, for her advice and support, and to Dr Helen Pulford and Dr Julia Cook for their 
helpful contributions at the beginning of this research project.   
 
Thank you to all of my wonderful family (grandparents, aunties, uncles, cousins – you know 
who you are!) and friends who have provided continuous enthusiasm, support, and 
encouragement throughout my years of studying.  Special thanks to my parents, Helen and 
Thomas, for always believing in me, for their valued advice, and for their endless love and 
support.  I could not have done it without you! And to my fiancé Alex, for his love, support, 
and friendship - I look forward to our life together!  I love you all very much.   
 
 
 
 
 
 
 
 
 
 
~ For my grandparents ~ 
 
 
Gerard Campbell 
Ellen Campbell 
Margaret Thomson  
Tommy Thomson  
 
    
 
Table of Contents  
 
 
 
 
CHAPTER 1:  Systematic Review                                                                                 1-26                                                                                             
 
Diagnostic Accuracy of the Montreal Cognitive Assessment (MoCA) for Detecting Mild 
Cognitive Impairment (MCI) and Dementia in Parkinson’s Disease:  A Systematic Review  
 
 
 
CHAPTER 2:  Major Research Project                                                                      27-48 
 
An Investigation into the Reliability of the Addenbrooke’s Cognitive Examination-III (ACE-
III) 
 
 
 
 
Appendices 
 
Systematic Review (Chapter 1)                                                                                    49-61                                                                            
Appendix 1.1 Publication Guidelines                                                                             50-58 
Appendix 1.2 Quality Rating Checklist                                                                                59 
Appendix 1.3 Quality Assessment Scores for each Included Paper                                60-61 
 
Major Research Project (Chapter 2)                                                                           62-86 
Appendix 2.1 Participant Information Sheet                                                                  63-66 
Appendix 2.2 Additional Information Sheet                                                                         67 
Appendix 2.3 Participant Instructions                                                                                 68 
Appendix 2.4 Vignette Orientation Information                                                                   69 
Appendix 2.5 Participant Consent Form                                                                              70 
Appendix 2.6 MVLS College Ethics Committee Approval Letter                                         71 
Appendix 2.7 NHS GG&C Board Approval Letter                                                         72-73 
Appendix 2.8  Major Research Project Proposal                                                           74-86 
 
 
 
 
1 
CHAPTER 1:  Systematic Review 
 
 
 
 
 
Diagnostic Accuracy of the Montreal Cognitive Assessment (MoCA) for 
Detecting Mild Cognitive Impairment (MCI) and Dementia in Parkinson’s 
Disease:  A Systematic Review  
 
 
 
 
Hollie Thomson¹* 
 
 
 
 
 
¹Mental Health and Wellbeing, Institute of Health and Wellbeing, University of Glasgow  
 
 
*Address for Correspondence:   
University of Glasgow 
Mental Health and Wellbeing  
Gartnavel Royal Hospital  
1st Floor, Administration Building 
1055 Great Western Road  
Glasgow 
G12 0XH 
Email: Hollie.Thomson@ggc.scot.nhs.uk 
 
 
 
 
Prepared in accordance with requirements for submission to the International Journal of 
Geriatric Psychiatry (Appendix 1.1) 
 
 
 
Submitted in part fulfilment of the requirements for the Degree of Doctorate in Clinical 
Psychology (D.Clin.Psy)  
 
 
Word Count: 8,229 
 
 
 
2 
Abstract 
 
Objectives: This systematic review examines the diagnostic accuracy of English and non-
English versions of the Montreal Cognitive Assessment (MoCA) for the detection of 
Dementia and Mild Cognitive Impairment (MCI) in Parkinson’s disease.   Methods:  A 
systematic search of relevant databases including PsycINFO, MEDLINE, EMBASE, and 
CINAHL was conducted from 2005 to December 2019.  Studies which fulfilled the inclusion 
criteria were reviewed using Standards for Reporting of Diagnostic Accuracy (STARD) 
guidance.  Results:  Twelve studies were included for review and were assessed as medium 
to low quality.  Studies generally reported good sensitivity for detecting MCI and dementia 
across different language versions of the MoCA however specificities were low, particularly 
for MCI, reducing diagnostic accuracy.  Optimal cut-off scores also varied, and findings 
were compromised by methodological limitations.  Conclusion:   The evidence base 
exploring the diagnostic accuracy of different language versions of the MoCA for 
individuals with Parkinson’s disease is not well established and further research is required.   
Future research should address the methodological limitations highlighted by this review 
through adherence to STARD guidelines.   
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Introduction 
Background  
Parkinson’s disease (PD) is a progressive, neurodegenerative disorder with a global 
prevalence of 0.5% to 4% in older adults aged 65 years and over (De Lau & Breteler, 2006).  
It is characterised by both motor symptoms (i.e. tremor, rigidity, bradykinesia, and postural 
instability) and non-motor symptoms (i.e. mood disturbance, fatigue, autonomic problems, 
and cognitive dysfunction) (Shulman, De Jager, & Feany, 2011).  Cognitive dysfunction is 
common in PD and can range from mild cognitive impairment (MCI) to dementia.    
Dementia is an umbrella term for a range of progressive conditions that are characterised by 
global cognitive decline and which significantly impact function and behaviour 
(Alzheimer’s Society, 2018a).  Mild cognitive impairment refers to cognitive decline which 
is more significant than what would be expected as part of the normal ageing process but is 
not as severe as dementia and does not significantly impact on functioning (Alzheimer’s 
Society, 2018b).  Although criteria for defining MCI and dementia in the general population 
have been proposed, the Movement Disorder Society Task Force (MDS-TF) developed 
specific ‘gold standard’ clinical criteria for diagnosing MCI and dementia in Parkinson’s 
disease (Litvan et al., 2012).  Research suggests that PD-MCI predicts the development of 
dementia, which can occur in up to 80% of people with PD (Aarsland et al., 2003) thus 
identifying PD-MCI early on is a clinical imperative.  PD-D can have a substantial impact 
on functioning, and is associated with reduced quality of life (Litvan et al., 2011), higher 
risk of institutionalisation (Emre et al., 2007) increased caregiver burden (Aarsland et al., 
1999), and higher mortality rates (Levy et al., 2002).  The early detection of cognitive 
dysfunction is therefore essential to ensuring early intervention and optimal management, 
and improving quality of life (NICE, 2006).   
Cognitive Screening Tests  
Given that the use of neuropsychological testing in routine clinical practice is limited due to 
time pressures and resource constraints, there is a need for a brief, simple, as well as accurate 
(i.e. reliable and valid), cognitive screening test that is acceptable to patients which can be 
used as part of the initial stage of a comprehensive dementia assessment (Cullen et al., 2007).  
The main aim of a cognitive screening test is to provide information about the presence, or 
absence, of cognitive impairment based on a person’s score on the test compared to 
referenced norms (Cullen et al., 2007).  Most screening tests utilise a cut-off score to 
establish the point at which a person’s score moves from being within the ‘normal’ range to 
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being within the ‘clinical’ range, i.e. indicating the presence of a cognitive impairment.  The 
psychometric robustness of a cognitive screening test is crucial to achieving this aim (Cullen 
et al., 2007).   
 
Two key aspects of test validity are sensitivity and specificity, and are concerned with the 
accuracy of a screening test relative to a reference standard.  Sensitivity refers to the 
proportion of individuals who have the target condition (reference standard positive) and 
who have a positive test result, and specificity refers to the proportion of individuals who do 
not have the target condition (reference standard negative) and who have a negative test 
result (Florkowski, 2008).  Thus, sensitivity may be defined as the extent to which a 
cognitive screening test correctly identifies all those with cognitive impairment, and 
specificity may be defined as the extent to which a cognitive screening test correctly 
identifies all those without cognitive impairment.  The sensitivity and specificity of a 
screening test will vary depending on the selected cut-off score; as the cut-off score of a test 
is manipulated to maximise sensitivity, the specificity of the test decreases and vice versa 
(Gifford and Cummings, 1999).  This inverse relationship between sensitivity and specificity 
is illustrated by a Receiver Operating Characteristic (ROC) curve. A ROC curve is a plot of 
the true positive rate (i.e. sensitivity) against the false positive rate (i.e. specificity) for the 
different cut-off points of a screening test and can therefore determine the optimal cut-off 
point for clinical use (Florkowski, 2008).   A perfect test will produce an area under the ROC 
curve of 1 (Gifford and Cummings, 1999).  A cognitive screening test with good sensitivity 
and specificity increases its clinical utility in that all those with a cognitive impairment are 
accurately classified as such, and that those without a cognitive impairment are not 
misclassified as impaired and referred on for further testing unnecessarily (Stolwyk et al., 
2014).  It should be noted however that in order to accurately assess the test validity of a 
screening measure, there must be a ‘gold standard’ test available for comparison.   
 
An increasing number of cognitive screening tests are being translated for use in multiple 
languages and across cultures.  It should be noted however that the clinical utility of a test 
will be limited without consideration of its reliability and validity in the country in which it 
is being used.  The psychometric properties of a cognitive screening test may vary between 
language versions due to differences in populations across studies such as age, education 
and cultural factors (Lewis et al., 2009; O’Driscoll & Shaikh, 2017).  For example, the 
quality of education varies across countries thus years of education may not be equivalent.  
Wong et al. (2009) pointed out that many older adults in Asian countries have received 
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significantly less education than their Western counterparts.  Poor translations, a lack of 
cultural equivalents, or words that are out with the general understanding or vocabulary of 
particular cultures may also affect the validity of a translated test.  Consequently, individuals 
from different countries and cultural backgrounds are unlikely to perform consistently on a 
cognitive screening test due to factors other than cognitive decline.   
The MoCA  
The Montreal Cognitive Assessment (MoCA; Nasreddine et al., 2005) is a brief cognitive 
screening test which takes approximately 10 minutes to administer, and assesses several 
cognitive domains including orientation, attention, memory, language, visuospatial function, 
and executive function (Nasreddine et al., 2005).   A maximum score of  30 can be obtained, 
with higher scores indicative of better cognitive performance.  A cut-off score of 26 or above 
is considered to be within the ‘normal’ range (Nasreddine et al., 2005).  The MoCA is easily 
accessed and is available in different language versions.  Although the MoCA was not 
developed specifically for patients with PD, it has been found to be useful in identifying 
individuals with MCI and dementia in non-PD populations (Larner, 2012).  The aim of the 
current paper therefore is to review the evidence in relation to the diagnostic accuracy of 
English and non-English versions of the MoCA in diagnosing MCI and/or dementia in 
patients with PD.   
 
Methods 
 
Search Strategy  
 
The following electronic bibliographic databases were searched from 2005 (year of 
publication of original MoCA paper) to December 2019: MEDLINE (OVID), EMBASE 
(OVID), PsychINFO (EBSCO), and CINAHL (EBSCO).  The following combinations of 
search terms were used in all databases: ([“Montreal Cognitive Assessment” OR “MoCA”] 
AND [“dementia” OR “Alzheimer’s” OR “cognitive impairment”] AND [“Parkinson* 
disease” OR “PD”]).  Given that Alzheimer’s is the most common form of dementia, it was 
included in the search terms. All searches were limited to English language.  Titles and 
abstracts of studies generated by initial searches were screened for relevance, and potentially 
eligible studies were reviewed in full against the inclusion criteria.  Reference lists of all 
included papers were also examined to identify any further relevant studies.   
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Inclusion and Exclusion Criteria  
 
The inclusion criteria were:   
 
1. Studies investigating the diagnostic accuracy of the MoCA for detecting mild 
cognitive  impairment (MCI) and/or dementia in patients with Parkinson’s disease. 
2. Studies investigating the diagnostic accuracy of both English and non-English 
versions of the MoCA.   
 
The exclusion criteria were:   
 
1. Studies that were not in English. 
2. Studies that did not use the Movement Disorder Society Task Force (MDS-TS) 
criteria for diagnosing MCI or dementia.   
3. Studies that used the MoCA to track changes in cognitive functioning over time 
rather than assessing diagnostic accuracy.  
4. Studies that used the MoCA as part of a wider cognitive assessment without 
providing information on diagnostic accuracy.   
5. Studies investigating the Short Form version of the MoCA (SF-MoCA) or the MoCA 
Basic (MoCA-B).  
6. Abstracts, response letters, reviews, and guides. 
 
Methodological Quality  
 
In order to rate the methodological quality of the studies included in this review, the study 
quality was critically appraised and scored by the author using the Standards for the 
Reporting of Diagnostic accuracy studies guidelines (STARD; Bossuyt et al., 2015; 
Appendix 1.2).  The STARD provides international consensus guidelines for evaluating 
diagnostic accuracy studies.  It consists of 31 items in total.  Each item has a maximum score 
of 2 points indicating that information is present, with 1 point indicating that information is 
present but with insufficient details, and 0 points indicating that information is missing.  The 
STARD therefore has a maximum score of 62 points.  Scores were summed to provide an 
overall quality score for each of the studies included.  An independent rater assessed 50% of 
the studies to certify that assessment scores were reliable. There was 92% agreement 
between raters, and where discrepancies occurred, consensus was reached through 
discussion.  Overall scores were then combined with an assessment of the extent to which 
the checklist criteria had been fulfilled to provide an overall quality rating of high (++), 
medium (+), or low (–) (NICE, 2014). 
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Figure 1 PRISMA flow diagram illustrating the search process  
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Results 
 
Outcome of Search Process  
 
A PRISMA flow diagram of search results is displayed in Figure 1 depicting the article 
search and review process.  The initial search yielded 2722 studies of which 410 were 
duplicates. Titles and abstracts were subsequently reviewed by the author using the study 
selection criteria outlined above which resulted in 26 remaining studies.  Upon full-text 
review of the remaining articles, 12 studies were included for review.    
 
Study Characteristics  
 
A summary of the study characteristics of all eligible studies is reported in Table 1.  The 
studies reported on English, Portuguese, Italian, Chinese, and Turkish versions of the 
MoCA.   The mean age of participants with Parkinson’s disease and either MCI or dementia 
in the studies ranged between 57 (Sobreira et al., 2015) and 73.4 (Dalrymple-Alford et al., 
2010).  Years of education ranged between 5.5 (Sobreira et al., 2015) and 16.2 (Hoops et 
al., 2009), and the male to female ratio varied between 16:15 (Sobreira et al., 2015) and 
299:96 (Hendershott et al., 2019).   
 
Information about diagnostic accuracy, including cut-off scores, sensitivity, and specificity, 
for each of the studies are reported in Table 2.  The cut-off scores for the different language 
versions of the MoCA included in this review ranged between 22.5 (Almeida et al., 2019) 
and 26 (Marras et al., 2013; Kandiah et al., 2014; Sobreira et al., 2015; Hendershott et al., 
2019) for MCI, and between 17.5 (Almeida et al., 2019) and 24.5 (Hoops et al., 2009) for 
dementia.  The sensitivity of the measures ranged between 77% (Brown et al., 2016) and 
93% (Kandiah et al., 2014) for MCI, and between 59% (Ozdilek et al., 2014) and 94% 
(Sobreira et al., 2015) for dementia.  Specificity values ranged between 27% (Sobreira et 
al., 2015) and 79% (Brown et al., 2016) for MCI, and between 76% (Almeida et al., 2019) 
and 89% (Ozdilek et al., 2014; Camargo et al., 2016) for dementia.  
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Table 1  Study Characteristics  
   Gender Age in years Years of education MoCA 
Study Language Participant type  male:female Mean ± SD 
 
Mean ± SD 
 
Mean ± SD 
 
Almeida et al. (2019)  Portuguese (Brazilian) PD-D (n = 25) 11:14 65.48 ± 8.67 5.63 ± 4.68 15.28 ± 3.6 
PD-MCI (n = 38) 18:20 66.53 ± 8.64 8.74 ± 5.54 20.76 ± 3.67 
PD-NC (n = 26) 19:7 57.15 ± 7.81 11.15 ± 4.7 25.42 ± 3.13 
Brown et al. (2016)  English PD-MCI (n = 58) 26:32 67.43 ± 10.06 15.17 ± 2.15 21.90 ± 3.55 
PD-NC(n = 53) 18:35 62.73 ± 8.61 15.98 ± 1.43 25.74 ± 2.57 
Camargo et al. (2016)  Portuguese (Brazilian) PD-D (n = 41) 26:15 69.78 ± 10.88 5.925 ± 4.99 14.66 ± 5.43 
PD-NC (n = 9) 6:3 66.89 ± 14.21 19.44 ± 6.38 22.44 ± 3.36 
Chen et al. (2013)  Chinese PD-D (n = 235) 112:123 69.3 ± 10.0 9 (6 - 12)* 18 (15 - 21)* 
Healthy (n = 381) 263:118 64.8 ± 10.6 12 (9 - 15)* 26 (24 - 28)* 
Dalrymple-Alford et al. (2010)  English PD-D (n = 21) 18:3 73.4 ± 6.7 12.9 ± 3.0 16.9 ± 4.0 
PD-MCI (n = 21) 15:6 71.5 ± 5.4 12.3 ± 3.1 23.2 ± 2.5 
PD-NC (n = 72) 50:22 64.5 ± 8.4 13.2 ± 3.0 26.7 ± 2.1 
Healthy (n = 47) 31:16 67.3 ± 9.3 13.7 ± 3.0 27.2 ± 1.9 
Federico et al. (2015) Italian PD-MCI (n = 22) 15:7 68.9 ± 7.2 8.3 ± 2.8  
PD-NC (n = 21) 12:9 67.5 ± 11.2 8.7 ± 3.1  
Hendershott et al. (2019) English PD-MCI or PD-D (n = 395) 299:96 67.8 ± 8.6 15.6 ± 2.6 23.7 ± 3.2 
PD-NC (n = 126) 59:67 63.4 ± 8.7 16.2 ± 2.5 27.4 ± 2.1 
Hoops et al. (2009)  English     PD-MCI or PD-D (n = 40) 33:7 68.1 ± 9.2 16.2 ± 3.1 22.2 ± 4.1 
PD-NC (n = 92) 67:25 63.9 ± 9.7 16.5 ± 3.1 26.2 ± 2.9 
Kandiah et al. (2014)  Chinese PD-MCI (n = 34) 20:14 70.49 ± 6.54 9.29 ± 3.14 23.35 ± 3.03 
PD-NC (n = 61) 47:14 64.34 ± 7.73 10.97 ± 3.30 27.66 ± 1.94 
Marras et al. (2013)  English PD-MCI (n = 46) 29:17 71.1 ± 4.8 15.3 ± 2.7 23.8 ± 3.3 
PD-NC (n = 93) 64:29 71.1 ± 5.7 16.1 ± 2.4 25.9 ± 2.4 
Ozdilek et al. (2014) Turkish PD-D (n = 9) 6:3 67.4 ± 7.8 5.6 ± 2.0 18.6 ± 3.7 
PD-MCI (n = 13) 10:3 63.3 ± 9.3 7.3 ± 3.0 20.6 ± 3.9 
PD-NC (n = 28) 18:10 58.3 9.5 10.0 ± 4.2 24.6 ± 3.9 
Healthy (n = 50) 22:28 62.3 9.4 10.0 ± 4.2 23.7 ± 4.1 
Sobreira et al. (2015)  Portuguese (Brazilian) PD-D (n = 16) 3:13 72.5 (53 - 81)* 5.5 (2 - 18)* 17 (7 - 24)* 
PD-MCI (n = 31) 16:15 57 (37 - 77)* 10 (0 - 20)* 23 (14 - 29)* 
PD-NC (n = 30) 10:20 61 (28 – 79)* 4 (1 - 20)* 23.5 (15 - 29)* 
 
Note: A blank space indicates that no information is available.  
Abbreviations: PD, Parkinson’s disease; PD-D, PD patient with dementia; PD-MCI, PD patient with mild cognitive impairment; PD-NC, PD patient with normal cognition.   
*Only the median (min-max) was reported in the article.   
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Table 2 Diagnostic accuracy information  
Study Target condition  Cut-off 
score 
Sensitivitya  Specificityb  AUC PPVc NPVd 
Almeida et al. (2019) 
 
Dementia         17.5 0.82 0.76    
MCI 22.5 0.85 0.71    
Brown et al. (2016) 
 
MCI 25 0.77 0.79 0.82   
Camargo et al. (2016) 
 
Dementia 19 0.88 0.89 0.91 0.97 0.61 
Chen et al. (2013)  
  
Dementia 23 0.70 0.77 0.83 0.59 0.85 
Dalrymple-Alford et al. (2010)  
 
Dementia 21 0.81 0.95 0.97 0.87 0.92 
Federico et al. (2015) 
 
MCI 25.5 0.82 0.67 0.79   
Hendershott et al. (2019) 
 
MCI   26 0.80 0.68 0.88 0.89 0.52 
Hoops et al. (2009) 
 
Dementia 24.5 0.82 0.75 0.87 0.38 0.96 
Kandiah et al. (2014)  
 
MCI 26 0.93 0.59 0.91   
Marras et al. (2013) 
 
MCI 26 0.83 0.44 0.71 0.42 0.83 
Ozdilek et al. (2014) 
  
MCI or Dementia 21 0.59 0.89 0.79 0.81 0.73 
Sobreira et al. (2015) 
 
MCI 26 0.84 0.27 0.50   
Dementia 21 0.94 0.68 0.86   
Note:  A blank space indicates that no information is available.  
Abbreviations: MCI, Mild Cognitive Impairment; AUC, Area Under the Curve; PPV, Positive Predictive Value; NPV, Negative Predictive Value.   
aSensitivity means that the test correctly identified those with MCI or dementia (i.e. the proportion of true positives). 
bSpecificity means that the test correctly identified those without MCI or dementia (i.e. the proportion of true negatives).   
cPPV means the proportion of people identified as having MCI or dementia who actually do have the condition. 
dNPV means the proportion of people identified as not having MCI or dementia who do not have the condition.
 
 
11 
 
Table 3 Quality assessment of included studies  
Study  STARD 
score/ 
number  
of items 
Main limitations  Rating 
of 
overall 
quality  
Almeida et al. (2019) 
 
34/62 No information on indeterminate or missing data, time interval not reported, non-blinded, small sample, a priori cut-off point 
for index test not reported, no participant flow chart  
- 
Brown et al. (2016) 
 
35/62 Power not calculated, non-blinded, no information on indeterminate or missing data, no participant flow chart, time interval 
not reported, a priori cut-off point for index test not reported, no study limitations reported 
- 
Camargo et al. (2016) 
 
35/62 Small sample, non-blinded, no information on indeterminate or missing data, power not calculated, time interval not reported, 
poorly defined sample, no participant flow chart, a priori cut-off point for index test not reported 
- 
Chen et al. (2013)  
 
42/62 A priori cut-off point for index test not reported, non-blinded, power not calculated, no information on indeterminate or 
missing data 
+ 
Dalrymple-Alford et al. (2010)  
 
42/62 Non-blinded, no information on indeterminate or missing data, power not calculated, a priori cut-off point for index test not 
reported 
+ 
Federico et al. (2015) 
 
37/62 Study timescale not reported, power not calculated, small sample, no information on indeterminate or missing data,  a priori 
cut-off point for index test not reported, time interval not reported 
- 
Hendershott et al. (2019) 
 
32/62 Non-blinded, no information on indeterminate or missing data, power not calculated, a priori cut-off point for index test not 
reported, time interval not reported, poorly defined sample, no study limitations reported, no participant flow chart  
- 
Hoops et al. (2009) 
 
42/62 Power not calculated, non-blinded, no information on missing data, a priori cut-off point for index test not reported, small 
sample 
+ 
Kandiah et al. (2014)  
 
36/62 Poorly defined sample, small sample, no participant flow chart, no information on indeterminate or missing data, non-blinded, 
power not calculated, time interval not reported, a priori cut-off point for index test not reported  
- 
Marras et al. (2013) 
 
42/62 No information on indeterminate data, power not calculated, no participant flow chart, a priori cut-off point for index test not 
reported, no study limitations reported 
+ 
Ozdilek et al. (2014) 
 
38/62 No participant flow chart, a priori cut-off point for index test not reported, no information on indeterminate or missing data, 
power not calculated, poorly defined sample, non-blinded, small sample 
- 
Sobreira et al. (2015) 
 
36/62 Non-blinded, a priori cut-off point for index test not reported, no information on indeterminate or missing data, power not 
calculated, no study limitations reported, small sample, no participant flow chart 
- 
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Quality Assessment  
 
Of the 12 studies included in this review, eight were assessed as low (–) quality and four 
were assessed as medium (+) quality (see Table 3).   Across all studies, an adequate 
description of the demographic and clinical characteristics of study participants was reported 
including age, gender, years of education, and Parkinson’s disease duration.  All but one 
study (Almeida et al., 2019) reported Parkinson’s disease severity using either the Hoehn 
and Yahr Scale or the Unified Parkinson’s Disease Rating Scale, Part three (UPDRS-III).  
This information is important given that the demographic and clinical characteristics of a 
sample can influence the diagnostic accuracy of a test and the generalisability of results 
(Bossuyt et al., 2015).  As per the inclusion criteria, all studies utilised the ‘gold standard’ 
Movement Disorder Society Task Force (MDS-TF) criteria as a reference standard to 
establish the presence or absence of MCI or dementia in study participants.  These criteria 
increase the validity of those diagnoses within this particular population (Litvan et al., 2012).  
All studies reported estimates of diagnostic accuracy including sensitivity and specificity, 
however, other measures of diagnostic accuracy, including positive and negative predictive 
values, were only reported in seven of the studies. All studies provided an adequate 
summation of the consequences of their findings and implications for clinical practice.  
 
There were a number of issues common to all or most of the studies.  Firstly, all of the 
studies, with the exception of two (Federico et al., 2015; Marras et al., 2013), failed to report 
on whether clinical diagnosis information and reference standard results were available to 
the assessors of the index test (i.e. the MoCA).  Assessors’ interpretation of MoCA results 
may have been influenced by their knowledge of the results of the reference standard thereby 
introducing review bias (Whiting et al., 2004).  Indeed, non-blinding of assessors could have 
resulted in more study participants being accurately diagnosed with MCI or dementia in the 
studies than would be the case in clinical practice.      Secondly, half of the studies failed to 
report the time interval between administration of the MoCA and the reference standard.  If 
the index test and reference standard are not performed at the same time, changes may occur 
in the target condition and/or other conditions during the interval period that could lead to 
biased estimates of test performance (Knottnerus & Muris, 2003).  Thirdly, no studies 
specified a priori defined cut-off scores prior to performing the MoCA, instead choosing the 
cut-off score which maximised test performance in their sample.  This can lead to estimates 
of sensitivity and specificity that are overly optimistic, particular in studies with small 
sample sizes.  When possible, studies should use prespecified cut-off points to improve the 
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validity of diagnostic accuracy findings (Leeflang et al., 2008).  Fourthly, there was little 
reporting of missing or indeterminate data across all of the studies which could also 
introduce biased estimates of diagnostic accuracy (Bossuyt et al., 2015).   And lastly, all of 
the studies with the exception of one (Almeida et al., 2019) failed to report on power 
calculation and intended sample size which has implications for the clinical relevance of 
study findings.  Sample size in most of the studies tended to be small which increases the 
likelihood of imprecise estimates of diagnostic accuracy (Bossuyt et al., 2015).   
 
All or most of the issues discussed above were relevant to the studies rated as low quality.  
It should be noted however that some of these issues may represent poor reporting quality 
rather than methodological flaws.  Nevertheless, these are items that the STARD guidelines 
consider to be essential and indeed their absence compromises the ability to draw valid 
conclusions about diagnostic accuracy.  Where these issues were given consideration, and 
at least partially addressed, studies were rated as medium quality.  Quality assessment scores 
for each of the items on the STARD for all included studies can be found in Appendix 1.3.    
Individual studies are described below and are categorised by language version of the 
MoCA.   
 
Review of Study Findings  
 
Italian  
 
One study evaluated the diagnostic accuracy of the Italian version of the MoCA in 
diagnosing MCI in Parkinson’s disease (Federico et al., 2015).  The results suggested that 
the MoCA could distinguish those with MCI with a sensitivity of 82%, and a specificity of 
67%, with a cut-off of 25.5.  The MoCA could not however reach a combined sensitivity 
and specificity of 80% at any cut-off value.  The validity of this study for drawing 
conclusions about the sensitivity and specificity of the Italian version of the MoCA in PD-
MCI is limited due to the small number of study participants (n = 43), the high prevalence 
of MCI included in the sample, and the strict selection criteria.  The study also failed to 
report the time interval between the reference standard and the index test which could have 
impacted on estimates of diagnostic accuracy.  Although the researchers in this study were 
blind to the clinical status of participants therefore enhancing study validity, the study was 
rated as low quality overall due to the aforementioned issues which reduce the 
generalisability of results, and compromise the ability to draw valid conclusions about 
diagnostic accuracy.      
 
 
 
14 
 
Turkish  
 
One study evaluated the validity of the Turkish version of the MoCA as a screening tool for 
detecting MCI and dementia in Parkinson’s disease (Ozdilek et al., 2014).  The results 
suggested that the optimal MoCA cut-off score for detecting any cognitive dysfunction was 
21 (sensitivity = 59%, specificity = 89%) however an appropriate cut-off score for 
differential diagnosis of MCI or dementia was not possible.  Interpretation is complicated 
here by the combined analysis of MCI and dementia. The discriminant validity and 
diagnostic accuracy of the Turkish version of the MoCA is therefore difficult to assess.  The 
small sample size (n = 50) in this study may also have compromised estimates of diagnostic 
accuracy.  This study was rated as low quality due to the issues discussed above, which 
compromise the validity of the conclusions that can be made as to diagnostic accuracy.   
 
Chinese 
 
In two studies, the authors investigated the diagnostic accuracy of the Chinese version of the 
MoCA for detecting MCI and dementia in Parkinson’s disease.  The studies confirmed the 
usefulness of the MoCA as a screening tool in Parkinson’s disease for both MCI (sensitivity 
= 93%, specificity = 59%) at a cut-off of 26 (Kandiah et al., 2014), and dementia (sensitivity 
= 70%, specificity = 77%) at a cut off of 23 (Chen et al., 2013) although specificities are 
fairly low compromising diagnostic accuracy.   In any case, the validity of both studies for 
drawing conclusions about the sensitivity and specificity of the Chinese version of the 
MoCA is limited due to a number of methodological issues.  Kandiah et al. (2014) was rated 
as low quality due to a failure to report the time interval between the reference standard and 
the index test, the small sample size included in the study (n = 95), and the non-blinding of 
assessors, all of which could have impacted on estimates of diagnostic accuracy.  Although 
some of these issues were relevant to Chen et al. (2013), this study included a larger sample 
size (n = 616), and reported that the reference standard and index test were completed on the 
same day which reduces biased estimates of test performance.   
 
Portuguese (Brazilian)  
 
The diagnostic accuracy of the Portuguese (Brazilian) version of the MoCA for detecting 
MCI and dementia in Parkinson’s disease was evaluated in three studies.  The findings from 
the first study (Almeida et al., 2019) suggested 85% sensitivity and 72% specificity at a cut 
off of 17.5 for detecting dementia, and 82% sensitivity and 76% specificity at a cut off of 
22.5 for detecting MCI, indicating that the MoCA has fairly good ability to screen for both 
 
 
15 
MCI and dementia in patients with Parkinson’s disease.  The findings from the second study  
(Sobreira et al., 2015) indicated better accuracy in detecting dementia among those who had 
Parkinson’s disease, with 94% sensitivity and 68% specificity at a cut-off of 21, however 
demonstrated less accuracy in screening for MCI with 84% sensitivity and 27% specificity 
at a cut-off of 26.  In the third study (Camargo et al., 2016), a cut-off score of 19 provided 
the best balance between sensitivity (88%) and specificity (89%) for detecting dementia in 
patients with Parkinson’s disease.  The authors suggested that as the MoCA is used as a 
screening test, a cut-off score with a higher sensitivity is perhaps more useful.  Similar to 
Sobreira et al. (2015), they found that a cut-off score of 21 provided higher sensitivity (93%) 
however specificity was low (56%).    All three studies were rated as low quality due to the 
methodological limitations discussed above in addition to small sample size and the non-
blinding of assessors which were common to all three studies.  Furthermore, although 
sensitivity was generally reported as good, specificities were relatively low, compromising 
diagnostic accuracy.   
 
English   
 
A total of five studies investigated the diagnostic accuracy of the English version of the 
MoCA.   Two of the studies examined the diagnostic accuracy of the MoCA in detecting 
dementia in Parkinson’s disease.  Both studies (Dalrymple-Alford et al., 2010; Hoops et al., 
2009) suggested that the MoCA has good overall discriminant validity as a screening tool 
for the detection of dementia.  It is notable however that different optimal cut-off scores 
were found in these studies, with a higher cut-off score of 24.5 (sensitivity = 82%, specificity 
= 75%) reported in the study by Hoops et al. (2009) compared to a cut-off of 21  (sensitivity 
= 81%, specificity = 95%) in Dalrymple-Alford et al. (2010). This variability may be 
explained by differences in demographic characteristics within the studies.  For example, the 
mean education (>16 years) reported by Hoops et al. (2009) was considerably higher than 
the mean education (>12 years) reported in the study by Dalrymple-Alford et al. (2010).  
The mean age in the Hoops et al. (2009) study was also around five years lower than that 
reported in the study by Dalrymple-Alford et al. (2010).  The population in the study by 
Hoops et al. (2009) may not be representative of the majority of patients with Parkinson’s 
disease and this may affect the generalisability of the results.   
 
Three of the studies examined the diagnostic accuracy of the English version of the MoCA 
in detecting MCI in Parkinson’s disease.  The findings from the first study (Hendershott et 
al., 2019) suggested 80% sensitivity and 68% specificity at a cut off of 26, indicating that 
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the MoCA is a sensitive screening tool for detecting MCI in Parkinson’s disease.  Marras et 
al. (2013) also reported a cut-off score of 26 with a sensitivity of 83% and a relatively low 
specificity of 44%.  The authors reported that a desirable combined sensitivity and specificity 
could not be achieved.  In the third study (Brown et al., 2016), the optimal cut-off score was 
slightly lower than the others at 25, with a sensitivity of 77%, and a specificity of 79%.  The 
studies by Hendershott et al. (2019) and Brown et al. (2016) were rated as low quality due 
to the methodological issues discussed above, which compromise the validity of the 
conclusions that can be made as to diagnostic accuracy.  Marras et al. (2013), on the other 
hand, reported the time interval between the reference standard and the index test, and 
ensured the blinding of assessors when administering the MoCA, which makes the 
conclusions drawn from this study more robust.  It was, therefore, given a medium quality 
rating.   
 
Discussion 
 
The aim of the current review was to investigate the diagnostic accuracy of English and non-
English versions of the MoCA in diagnosing MCI and/or dementia in patients with PD.   
Although studies generally reported good sensitivity for detecting MCI and dementia across 
different language versions of the MoCA, specificities in many of the studies were fairly 
low, reducing diagnostic accuracy.  Study findings were also compromised by a number of 
methodological flaws.   Indeed, across most of the studies reviewed there was a lack of 
information on: blinding of assessors, the time period between administration of the MoCA 
and the reference standard, a priori defined cut-off thresholds, and power calculation and 
intended sample size.  As a consequence, it is not possible to know the potential for biased 
estimates of test performance and thus diagnostic accuracy.  Future studies investigating the 
MoCA would benefit from including this information.    
 
The review also found that optimal cut-off thresholds across studies, even within the same 
language versions, varied.   Variance in optimal cut-off scores between studies may have 
been due to differences in populations across studies, such as age, education, and cultural 
factors (Lewis et al., 2009; O’Driscoll & Shaikh, 2017).   Indeed, the mean age across studies 
differs by over 16 years between the youngest and oldest sample.  Large variances also exist 
in mean education across studies ranging from 5.5 to 16.2 years.   In addition, the proportion 
of patients with cognitive impairment in the samples varied widely across studies from 22% 
(Sobreira et al., 2015) to 82% (Camargo et al., 2016) which may also have impacted on the 
differences in findings.  To be fit for clinical use, screening tools must have statistically 
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robust cut-off scores to allow distinction between the presence or absence of cognitive 
impairment (Lezak et al., 2004).  The variance in obtained optimal cut-off scores found in 
this review is an issue potentially compromising the clinical utility of the MoCA in PD 
populations.  This could be addressed in future research through the use of a priori defined 
cut-off thresholds (Leeflang et al., 2008). 
 
In several of the studies, particularly the non-English language studies, the optimal 
diagnostic cut-off scores for detecting MCI or dementia in PD were lower than previously 
published normative data for the MoCA (Nasreddine et al., 2005).  Differences in 
demographics in the original study when compared to the studies included in this review 
may account for this variance.  The original validation data was based on English and French 
versions of the MoCA and although the mean age in the original study was higher than most 
of the studies included in this review, the mean years of education was also significantly 
higher.  The MoCA does not account for premorbid functioning or years of education which 
limits the ability of clinicians to draw conclusions about whether an individual’s cognitive 
decline is greater than expected for their age and years of education (Gagnon et al., 2013). 
Given that some items in the MoCA are likely to be influenced by education (i.e. phonemic 
verbal fluency, verbal abstraction), it follows that individuals with lower levels of education 
are likely to score lower on the MoCA (Nasreddine et al., 2005).  Furthermore, years of 
education may not be cross-culturally equivalent, with many individuals in middle Eastern 
and Asian countries having received somewhat less education than those in Western 
countries (Lee et al., 2008).   Premorbid functioning and culture have been shown to have 
an impact on other screening tool performance (Pedrazaa et al., 2012), and should be 
measured in relation to the MoCA.   
 
Similar findings were reported in a review study investigating the cross-cultural applicability 
of the MoCA in screening for MCI (O'Driscoll & Shaikh, 2017).  A wide range of cut-off 
scores were found across and within countries, and as a consequence individuals could be 
considered as cognitively impaired or within the ‘normal range’ using the same cut-off score.  
Thus, the criteria to diagnose cognitive impairment may differ between countries based on 
educational and cultural variation, and the use of a universal cut-off score may lead to a 
sampling bias and inaccurate conclusions about an individual’s cognitive ability (O'Driscoll 
& Shaikh, 2017).  This highlights the need for population-based norms for each language 
version of the MoCA, and the need for further research on population characteristics other 
than age, education, and culture which may influence MoCA scores.   
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Although not specifically highlighted within the studies, it should be noted that level of 
motor impairment may also have an influence on test performance (Koski, 2013).   
Functional limitations that are common to PD populations may impact the response process 
and impede assessment of cognitive ability.  Interestingly,  Nazem et al. (2009) found that 
severity of motor impairment in PD populations was not associated with performance on the 
MoCA, particularly those items requiring motor skills.  This would suggest that PD 
symptoms do not preclude assessment	of	cognitive	ability	using	the	MoCA.			Ultimately, 
decisions about a patient’s ability to complete a valid cognitive assessment will be based on 
the clinician’s clinical judgment with some clinicians choosing to omit problematic items 
and interpret the resulting score with caution (Koski, 2013).   
 
There are a wide range of cognitive screening tests available for detecting MCI and dementia 
however several diagnostic accuracy studies have shown that the MoCA performs 
favourably (Roalf et al., 2013; Tsio et al., 2015).    In PD populations, research suggests that 
when compared with the Mini Mental State Examination (MMSE), which is amongst one of 
the most widely used screening tests, the MoCA is more sensitive and accurate, particularly 
in relation to detecting early cognitive impairment.  The ability of the MoCA to detect a 
decline in the cognitive functions commonly affected in PD (i.e. reasoning, planning, and 
executive functions) has been widely reported as the main advantage of the MoCA over the 
MMSE (Camargo et al., 2016; Chou et al., 2010; Dalrymple-Alford et al., 2010; Hoops et 
al., 2009). Indeed, the use of the MMSE as a screening test in PD has been challenged due 
to its limited executive function assessment (Bugalho & Vale, 2011).   
 
These concerns have led to some doubts about the applicability of the MDS-TF criteria for 
diagnosing MCI and dementia in Parkinson’s disease since the cognitive assessment used to 
determine the presence of cognitive impairment is based on the MMSE (Ohta et al., 2014).  
Although it is widely acknowledged that the development of specific guidelines for 
diagnosing MCI and dementia in PD populations is an important milestone, it is essential 
that cognitive impairment in this population is detected early and diagnosed accurately.   
Since the development of the MDS-TF criteria, many studies have assessed its validity and 
have reported variable findings with most concluding that the accuracy of the MMSE was 
not satisfactory and that it lacked sensitivity (Barton et al.,2012; Isella et al., 2014; Ohta et 
al., 2014).  Despite this, some studies have found that the MDS-TF criteria are more sensitive 
for diagnosing cognitive impairment than the previously widely used Diagnostic and 
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Statistical Manual of Mental Disorders, 4th edition (DSM-IV) definition (Martinez-Martin 
et al., 2011).  In any case, research suggests that the current MDS-TF criteria for diagnosing 
cognitive impairment in PD populations requires refinement. 
 
Limitations of the Review  
 
Due to the strict inclusion criteria, only a small number of studies were included in this 
review.  Although a comprehensive and rigorous search strategy was implemented, there is 
always a possibility that papers may have been missed. The absence of a second rater for 
study selection is another clear limitation.  In addition, the review included only English 
language studies which may have led to the exclusion of relevant research.  In relation to the 
quality assessment process, the overall quality ratings (i.e. high, medium, or low) given to 
the studies was to assist the reader’s interpretation of study quality however the cut-off 
scores used to categorise study robustness were arbitrary.  Moreover, although the use of 
total scores can help to summarise the quality of each of the papers, reliance on total scores 
may fail to identify the studies which are at an increased risk of bias in some key areas and 
thus analysis of individual components of methodological quality should be considered 
(O’Conner et al., 2015).   
 
Areas for Future Research and Clinical Practice  
 
The variability of cut-off scores found in this review both across and within different 
language versions of the MoCA for detecting MCI and dementia in PD populations 
highlights the need for caution in applying them without first taking into consideration the 
effects of age, education, and cultural difference (Rossetti et al., 2011). The low quality of 
diagnostic accuracy studies emphasises the importance of using the MoCA as a screening 
tool only, and interpreting test scores within the context of a more comprehensive assessment 
(Wong et al., 2015).  There is a clear need to build up an evidence base for specific cut-off 
scores for specific language versions of the MoCA by seeking to evaluate the performance 
of cut-off thresholds reported in previous studies rather than simply reporting the cut-off 
score which maximises test performance in any given sample.  Improving the validity of 
diagnostic accuracy studies through adherence to STARD guidelines is also essential for 
future research.   
 
 
 
 
 
 
20 
Conclusion 
 
Although the studies included in this review generally reported good sensitivity for detecting 
MCI and dementia across different language versions of the MoCA, specificities in many of 
the studies were fairly low, particularly for MCI, reducing diagnostic accuracy.  Moreover, 
optimal cut-off thresholds, even within particular language versions, varied, compromising 
the clinical utility of the MoCA in PD populations.  Future research should address the 
methodological limitations highlighted by this review through adherence to STARD 
guidelines.   
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Abstract 
 
 
Background:  Dementia is a leading cause of disability amongst older adults in the 
developed world.   In recent years, an increasing emphasis has been placed on the early 
detection and diagnosis of dementia, and timely access to post-diagnostic support.  Cognitive 
screening tests are essential tools in facilitating the process of early detection and dementia 
diagnosis and are currently widely used in clinical practice.    The Addenbrooke’s Cognitive 
Examination-III (ACE-III) is one such tool. Despite it being recommended in several 
evidence-based guidelines and being widely used in the NHS, the rater reliability of the 
ACE-III has never been formally evaluated.  Aims:  To investigate rater accuracy in scoring 
the ACE-III both in terms of its total and sub-category scores across different raters and by 
the same raters at two different time points.  A secondary exploratory analysis examines 
whether scoring accuracy is affected by participants’ experience of using the ACE-III and/or 
whether they have had formal training on how to administer and score the ACE-III.  
Methods:  A filmed vignette of the ACE-III being administered to an older adult actor (mock 
patient) was used to assess scoring accuracy across different raters.  The vignette has pre-
determined ‘true’ scores.  Participants were asked to view the filmed vignette whilst 
simultaneously completing an ACE-III scoring sheet.   Following a two-month period, 
participants were invited back to view and score the same vignette again to assess intra-rater 
reliability.  Participants were NHS staff working in Older People’s Community Mental 
Health Teams who routinely administer and score the ACE-III as part of their clinical 
practice. Results and Conclusions:   The inter- and intra-rater scoring accuracy of the ACE-
III is generally good, with error mainly accounted for by the domains which require more 
subjective judgements, namely, the visuospatial and language tests.  Health professionals 
should therefore take these findings into account when scoring the ACE-III, and utilise the 
ACE-III administration and scoring guide to help improve accuracy.  If all health 
professionals score the ACE-III in a consistent manner, the accurate and early identification 
and management of those individuals with a dementia will be improved.    
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Introduction 
Background  
Dementia is an umbrella term for a range of progressive conditions that are characterised by 
global impairment of cognitive functioning (Alzheimer’s Society, 2018).  Dementia is a 
leading cause of disability amongst older adults in the developed world, and constitutes one 
of the most significant, and costly, challenges currently facing health and social care services 
(Milne et al ., 2008).  In the UK alone, there are approximately 850,000 people currently 
living with a dementia (Alzheimer’s Society, 2018).  Given that age is the biggest risk factor 
for developing a dementia, and that the average life expectancy is increasing, it is not 
surprising that the incidence and prevalence of dementia is expected to rise rapidly over the 
next several decades.  Indeed, it is estimated that by 2051 there will be around two million 
people in the UK living with a dementia (Alzheimer’s Society, 2018).  Over the past decade, 
the Scottish Government has made dementia a public health priority and has set out a range 
of commitments and objectives to improve the quality of care for individuals with a 
dementia, with increasing emphasis being placed on early detection and diagnosis, and 
timely access to post-diagnostic support (Scottish Government, 2017).  Early detection of 
dementia is essential to ensuring early intervention and management of the condition, and 
improving quality of life (Scottish Government, 2017).         
 
The Role of Cognitive Screening Tests in Dementia Diagnosis  
 
The National Institute for Health and Care Excellence (NICE, 2018) recently published 
guidelines on the diagnosis and management of dementia which stipulate the use of a 
validated brief structured cognitive screening test as part of the initial stage of a 
comprehensive dementia assessment. Indeed, the assessment of cognitive functioning is 
central to the process of early detection and diagnosis of dementia and is therefore arguably 
one of the most important assessments made by clinicians in clinical practice (Machado et 
al ., 2015).  In the context of time constraints, the efficient early detection of dementia 
requires the use of an objective cognitive screening test which is brief, reliable, easy to 
administer, and acceptable to patients (Cullen et al., 2007; Villarejo & Puerta-Martin, 2011).   
It is not surprising then that in recent years there has been an increase in the number of 
dementia screening tests proposed and studied.    
 
The main aim of a cognitive screening test is to provide information about the presence, or 
absence, of a cognitive impairment (Lezak et al., 2004).  This is often inferred from the 
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individuals’ score on the test compared to referenced norms (Cullen et al., 2007).  A central 
feature of most screening tests is the ‘cut off’ score, that is, the point at which an individual’s 
score moves from being within the ‘normal’ range to being within the ‘impaired’ range, i.e. 
indicating the presence of a dementia.  The success of a screening test in achieving this aim 
undoubtedly lies in its psychometric robustness (Cullen et al., 2007).  Cognitive screening 
tests should have good sensitivity and specificity to ensure that individuals with a cognitive 
impairment are not missed and that individuals without a cognitive impairment are not 
misidentified as impaired and referred on for further testing unnecessarily (Stolwyk et al., 
2014).   
 
One of the most important attributes of any assessment instrument is its reliability, that is, 
the extent to which the test produces consistent measurements when repeated under replicate 
conditions (Van Belle & Arnold, 2000).  There are a number of factors which may influence 
the reliability of a test including individual factors (i.e. mood, fatigue, and motivation), 
environmental factors (i.e. temperature and noise), and rater factors (i.e. training, experience, 
judgement).  These factors are sources of measurement error in the assessment process.   If 
these measurement errors did not exist, one would expect that an individual would obtain 
the same test score, their ‘true’ score, each time they took the test.  It is generally accepted 
however that the observed score on a test equates to the ‘true’ score plus some degree of 
measurement error (Trochim, 2006).  Thus, the extent to which a cognitive test can minimise 
the impact of measurement errors, and ensure that the score obtained is as close to the 
individuals ‘true’ score as possible, is an indication of its reliability (Trochim, 2006).  Inter-
rater reliability is the level of scoring consistency between raters evaluating the same test.   
However, agreement between raters does not necessarily equate to scoring accuracy when 
evaluating a test, since raters may show high levels of agreement but show low levels of 
accuracy.  Therefore, rater accuracy in scoring tests across different raters is an important 
aspect of reliability that must be taken into consideration in inter-rater reliability studies.  
Intra-rater reliability assesses scoring consistency by the same raters at two different time 
points.   
 
The ACE-III as a Cognitive Screening Test for Dementia 
 
The Addenbrooke’s Cognitive Examination, now in its third edition (ACE-III), is one of the 
cognitive screening tests recommended by the Scottish Intercollegiate Guideline Network 
(SIGN) in its guideline on the Management of Patients with Dementia (SIGN, 2006).  The 
ACE-III is comprised of five subscales, each representing a cognitive domain; Attention, 
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Memory, Fluency, Language, and Visuo-spatial.  A maximum score of 100 can be obtained, 
with higher scores indicative of better memory and cognitive performance.   The ACE-III is 
designed to be sensitive to the early stages of dementia.   Cognitive domains within the ACE-
III have been validated against a battery of standardized neuropsychological tests, with high 
levels of correlation between the domain scores and targeted tests used in the assessment of 
attention, language, verbal memory and visuospatial function (Hsieh et al., 2013). The ACE-
III also compared favourably with its predecessor, the ACE-R, with similar levels of 
sensitivity and specificity, in the assessment of cognitive deficits in people with Alzheimer’s 
disease and fronto-temporal dementia (Hsieh et al., 2013). The ACE-III shows high 
sensitivity and specificity for mild cognitive impairment (MCI) at a cut-off of 88 (sensitivity 
= 1.0; specificity = 0.96) and dementia at a cut-off of 82 (sensitivity = 0.93; specificity = 
1.0) (Hsieh et al., 2013). It takes approximately 15 minutes to administer the ACE-III and it 
therefore meets the requirements of a screening test which is time efficient (Cullen et al., 
2007).  There are three versions of the ACE-III available to reduce any practice effects with 
repeat testing.  Appropriate use of the ACE-III requires clinicians who are able to accurately 
administer, score, and interpret the test.  The ACE-III was devised for use by a range of 
professional groups who work with patient populations that require cognitive screening 
including General Practitioners (GPs), Psychiatrists, Nurses, Occupational Therapists 
(OTs),  and Clinical Psychologists (CPs).  Despite this, validation studies for the ACE-III 
have generally utilised Psychologists, Neurologists, and Neuropsychologists to administer 
and score the test (Takenoshita et al., 2019).   
 The Current Study  
Although the psychometric properties of cognitive screening tests are widely reported, there 
is a dearth of research exploring the rater reliability and scoring accuracy of such tests among 
clinicians who routinely use them in clinical practice (Newman et al ., 2018).  Previous 
studies examining test scoring on cognitive screening measures have found high rates of 
error (Crawford, 2010; Kozora, 2018; Sullivan, 2000) which highlights the importance of 
usability research, and ensuring that tests are used appropriately in real-world settings.  
Similarly, the consistency with which a test is scored by a range of clinicians is rarely 
reported.  This is particularly relevant when there are items on a test which require more 
subjective scoring judgements.       
Despite being recommended in several evidence-based guidelines as a screening test for 
dementia, and being widely used in the NHS, the rater reliability of the ACE-III has never 
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been formally evaluated.  As with any method of objective testing, it is essential to establish 
whether the ACE-III is accurately and consistently scored across different raters and by the 
same raters at different time points.  Indeed, this is highly relevant to ensuring the accurate 
and early identification and management of those individuals with a dementia.   
 
Aims 
 
This study investigated rater accuracy in scoring the ACE-III.  It explored how accurately 
the ACE-III was scored both in terms of its total and sub-category scores across different 
raters and by the same raters at two different time points.    It also considered whether scoring 
accuracy was affected by participants’ experience of using the ACE-III and/or whether they 
had formal training on how to administer and score the ACE-III.  
 
Research Questions 
 
The specific research questions in relation to this study are: 
(i) Do participants’ ACE III total scores differ significantly from the ACE III ‘true’ 
score? 
(ii)  Do participants’ ACE-III sub-category scores differ significantly from the ACE-III 
‘true’ scores? 
(iii)  What is the test-retest scoring consistency across two different time points?   
 
Secondary Exploratory Analysis 
 
A secondary exploratory analysis was conducted to examine whether scoring accuracy was 
affected by participants’ experience of using the ACE-III and/or whether they had received 
formal training on how to administer and score the ACE-III.  
 
Methods 
 
Participants  
The participants in this study were NHS staff working in Older People’s Community Mental 
Health Teams in Greater Glasgow and Clyde who routinely administer and score the ACE-
III as part of their clinical practice.  Participants were recruited from several groups of 
professionals including, Clinical Psychologists, Community Psychiatric Nurses (CPNs), 
Occupational Therapists (OTs),  and Care Home Liaison Nurses (CHLNs).   
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Eligibility Criteria  
 
To be considered eligible for inclusion in this study, participants were required to have 
administered and scored the ACE-III independently in clinical practice on at least one 
occasion with an older adult patient.  Participants were excluded if they had not administered 
the ACE-III in clinical practice.  Some participants had previously received training on how 
to administer and score the ACE-III; this did not preclude them from inclusion in the study.   
 
Justification of Sample Size  
 
A-priori sample size calculation was completed using G*Power (Faul et al., 2007) with an 
assumed power of 0.8 and an error value of 0.05.  Calculations were based on the method of 
data analysis required to answer the main research question; one sample t-tests (or the non-
parametric equivalent) to compare differences between participants’ ACE-III total and 
domain scores and the predetermined ‘true’ scores.    G*Power (Faul et al., 2007) indicated 
that a minimum of 34 participants would be required to detect a medium effect size.  A 
medium effect size was deemed to be sufficient enough to detect a clinically significant 
difference, that is, a difference large enough to alter interpretation of the ACE-III results 
(Crawford, 2010). 
 
Measures  
 
The Addenbrooke's Cognitive Examination-III (ACE-III) was the primary outcome 
measure.  
 
Design Procedure 
 
Permission was given to use a filmed vignette from the online NHS Education for Scotland 
(NES) ACE-III Trainer programme for the purposes of this study.  The University of 
Glasgow media services originally filmed and produced the vignette.  The vignette is of a 
Clinical Psychologist administering the ACE-III to an older adult actor (mock patient).  The 
vignette has pre-determined ‘true’ scores which had been agreed upon by two experienced 
Clinical Psychologists.  Given that the scripts for the vignettes were written jointly by 
Clinical Psychologists with extensive neuropsychological experience within older adult 
services, and that the answers were also co-produced, there was 100% agreement on what 
the ‘true’ scores should be.  Pre-determined ‘true’ scores allow for scoring consistency to be 
investigated separately from administration consistency.   The vignette has a ‘true’ total 
score of 63/100.  
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Research Procedure 
 
Participants were recruited from Older People’s Community Mental Health Teams across 
NHS Greater Glasgow and Clyde.  Potential participants were invited to take part in the 
study via email and received an information sheet about the study (Appendix 2.1).  
Participants who opted in to the study were invited to a research session lasting 
approximately one hour, where they watched a vignette whilst simultaneously completing 
an ACE-III scoring sheet.  The vignette was shown to participants in groups and played on 
a projector screen. Participants were asked to view the vignette once and were not be 
permitted to pause or rewind it, reflecting actual clinical practice.  The ACE-III 
administration and scoring guide was made available to participants on request.  Participants 
were not permitted to consult each other regarding scoring and were blinded from each 
other’s ratings.  Participants were also asked not to discuss their scoring after the session.  In 
addition to scoring the vignettes, participants were also asked to complete an information 
form detailing their profession, ACE-III experience, and whether or not they had completed 
any formal training in using the ACE-III (Appendix 2.2).  A standardised set of instructions 
were given verbally to each group of participants prior to commencing the study (Appendix 
2.3).  Participants were also given the correct orientation information for the vignette 
(Appendix 2.4).  Consent forms were signed at the group session prior to participation 
(Appendix 2.5). To evaluate intra-rater reliability, participants were invited back after a 
period of approximately two months to view and score the same vignette again, under the 
same conditions and in an identical manner to the first time point.  Participants were asked 
to confirm ongoing consent to participate in the study given the passage of time.  Participants 
did not have access to their previous ratings.  Participants were also asked for an update as 
to whether they had received any additional ACE-III training since the previous test session.    
 
Ethical Approval  
 
Prior to the commencement of the study, ethical approval was sought and obtained from the 
College of Medical, Veterinary and Life Sciences (MVLS) Ethics Committee (Appendix 
2.6). Approval was sought and obtained from NHS Greater Glasgow and Clyde R&D 
(Appendix 2.7).   
 
Data Analysis  
 
Descriptive statistics including proportions and standard deviations were used to analyse the 
variation of test scores from the ‘true’ scores. Percentages were also used to determine how 
many participants correctly identified the ‘true’ total, domain, and sub-domain scores.  The 
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number of participants scoring consistently with the true score, within two points, or 
deviating by three or more points is reported. A two point discrepancy is reported as this was 
considered likely to be acceptable in clinical practice and was also used by Crawford (2010) 
in a previous investigation of scoring reliability of the ACE-R.       
 
All statistical analyses were carried out using IBM® SPSS Statistics, version 26.0.  Initial 
investigations revealed that the data did not meet the assumptions of normality and a non-
parametric approach to statistical analysis was taken.  One sample Wilcoxon Signed-Rank 
tests were used to compare whether participants’ ACE-III total scores differed significantly 
from the predetermined ‘true’ scores, and to investigate whether the results obtained differed 
significantly from the ‘true’ domain scores.   Paired samples Wilcoxon Signed-Rank tests 
were used to compare differences between participants’ total and domain scores between 
session one and session two.   Correlational methods were used to explore intra-rater 
reliability, that is, whether participants’ ACE-III scores were consistent across two different 
time points.  Mann-Whitney U tests  were used to explore whether scoring accuracy was 
affected by participants’ experience of using the ACE-III and/or whether they had received 
formal training on how to administer and score it.   
 
 
Results 
 
Forty-one participants (38 females; 3 males) consented to take part in the study; 31 
Community Psychiatric Nurses (CPN’s), 6 Occupational Therapists (OT’s), 1 Clinical 
Psychologist (CP), and 3 Care Home Liaison Nurses.  Participants’ length in post ranged 
from one year or less to 24 years (M = 8.6, SD = 6.9).  All participants attended the first 
research session of the study.  One participant did not sum items to provide domain and total 
scores and this was therefore treated as missing data and excluded from relevant analyses.  
Of the 41 participants who completed the first part of the study, 37 attended the second 
research session approximately two months later.     
 
 
Scoring Accuracy for Session One  
 
Table 1 summarises the accuracy figures for participant ACE-III total, domain, and sub-
domain scores.  Participant total scores for the ACE-III vignette ranged from 58 to 68 points 
(M = 63.05, SD = 2.3).  Twenty percent of participant total scores matched the predetermined 
‘true’ score (TS), while 48% of total scores deviated from the TS by 1-2 points, and 32% 
deviated from the TS by 3-5 points.  No participant total scores deviated from the TS by 
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more than 5 points.  Forty-five percent of participant ACE-III scores were higher than the 
TS, while around 35% were lower, indicating an overall tendency towards over-scoring.   
Scoring errors were highest within the language and visuospatial domains, with 63% and 
76% of participant scores deviating from the TS respectively.  At the sub-domain level, this 
deviation from the TS was mainly accounted for by scoring errors on the clock drawing item 
and on the single word repetition item, with 66% of participant scores deviating from the TS 
on both items.  There was a tendency towards over-scoring within the language domain (M 
= 21.7, SD = .66) and on the clock drawing item (M = 1.4, SD = .58) while a tendency for 
under-scoring was observed within the visuospatial domain (M = 7.4, SD = .77) and on the 
single word repetition item (M = 1.7, SD = .52).  Errors were present but observed less for 
the fluency (20%), memory (29%), and attention (46%) domains.    
 
One sample Wilcoxon Signed-Rank tests were conducted to compare differences between 
participant total and domain ACE-III scores and the TS.  The results indicated that there was 
a statistically significant difference between participant scores and the TS on the language 
(Z= -4.435, p < .001) and visuospatial (Z = 3.970, p <.001) domains, with large effect sizes.  
No statistically significant difference was found between participant scores and the TS on 
the attention, memory, or fluency domains.  The results also indicated that there was not a 
statistically significant difference between participant total ACE-III scores and the TS.  
Table 2 presents the median, interquartile range, and test statistics.   
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Table 1  Accuracy for ACE-III total, domain, and sub-domain scores  
 ACE-III 
True Score 
(TS) 
Same as 
TS at 
Session 1 
(S1) 
+/- 2 points 
from TS 
(S1) 
+/- 3 or 
more 
points 
from TS 
(S1) 
Same as 
TS at 
Session 2 
(S2) 
+/- 2 points 
from TS 
(S2) 
+/- 3 or 
more 
points 
from TS 
(S2) 
ACE-III (%) 
 
Total  
 
63/100 
 
20 
 
48 
 
32 
 
24 
 
65 
 
11 
Attention  (%) 
Orientation 1  2/5 100 - - 100 - - 
Orientation 2  5/5 100 - - 100 - - 
Registration  3/3 95 5 - 100 - - 
Numbers  3/5 71 29 - 71 29 - 
 
Domain Total  
 
13/18 
 
51 
 
44 
 
2 
 
66 
 
34 
 
- 
Memory (%) 
Recall  3/3 100 - - 100 - - 
Anterograde  6/7 98 2 - 100 - - 
Retrograde  3/4 90 10 - 95 5 - 
Name & 
Address Recall  
2/7 68 32 - 68 32 - 
Name & 
Address Recog. 
3/5 63 37 - 81 19 - 
 
Domain Total  
 
17/26 
 
71 
 
24 
 
5 
 
67 
 
30 
 
3 
Fluency  (%) 
Letters 2/7 93 7 - 95 5 - 
Animals  2/7 90 10 - 84 16 - 
 
Domain Total 
 
4/14 
 
80 
 
20 
 
- 
 
84 
 
16 
 
- 
Language  (%) 
Comprehension 
Pencil/Paper  
3/3 100 - - 100 - - 
Comprehension 
Pictures  
3/4 100 - - 97 3 - 
Object Naming  12/12 100 - - 100 - - 
Reading  1/1 100 - - 100 - - 
Proverb 
Repetition 1 
1/1 100 - - 100 - - 
Proverb 
Repetition 2 
0/1 100 - - 97 3 - 
Single Word 
Repetition  
1/2 34 66 - 32 62 6 
Sentence 
Writing  
0/2 98 2 - 97 3 - 
 
Domain Total  
 
21/26 
 
37 
 
63 
 
- 
 
35 
 
62 
 
3 
Visuospatial  (%) 
Dots  2/4 93 7 - 87 13 - 
Letters  4/4 100 - - 97 3 - 
Clock  2/5 34 66 - 43 57 - 
3D Cube  0/2 90 10 - 92 8 - 
Infinity  0/1 100 - - 100 - - 
 
Domain Total 
 
8/16 
 
24 
 
76 
- 
- 
 
30 
 
70 
- 
- 
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Table 2 Summary of one sample Wilcoxon Signed-Rank tests  
                                                                                                   Test statistics (N = 40) 
 True 
Score 
(TS) 
Mdn Interquartile     
Range 
  
Z 
 
P 
 
r 
        
Attention  13 13 12 - 13  -1.035 0.300 0.16 
Memory  17 17.5 16.25 – 18  -1.078 0.281 0.17 
Fluency  4 4 4 – 4  -0.378 0.705 0.06 
Language  21 22 21 – 22  -4.435 0.000 0.70 
Visuospatial  8 7 7 – 8  3.970 0.000 0.63 
Total  63 63 62 - 64.75  -.189 0.850 0.03 
 
Scoring Accuracy for Session Two  
 
Participant total scores for the ACE-III vignette ranged from 60 to 66 points (M = 63.19, SD 
= 1.6).  Twenty-four percent of participant total scores matched the predetermined TS, while 
65% of total scores deviated from the TS by 1-2 points, and 11% deviated from the TS by 3 
points.  No participants deviated from the TS by more than 3 points.  Forty-six percent of 
participant ACE-III scores were higher than the TS, while around 30% were lower, again 
indicating an overall tendency towards over-scoring.   
 
Scoring errors were again highest within the language and visuospatial domains, with 65% 
and 70% of participant scores deviating from the TS respectively.  At the sub-domain level, 
this deviation from the TS was again mainly accounted for by scoring errors on the clock 
drawing item and on the single word repetition item, with 68% and 57% of participant scores 
deviating from the TS respectively.  There was a tendency towards over-scoring within the 
language domain (M = 21.6, SD = .86) and on the clock drawing item (M = 1.4, SD = .50) 
while a tendency for under-scoring was observed within the visuospatial domain (M = 7.5, 
SD = .87) and on the single word repetition item (M = 1.7, SD = .56).  Errors were present 
but observed less for the fluency (16%), memory (33%), and attention (34%) domains.  
Table 1 summarises the percentage accuracy for participant ACE-III total, domain, and sub-
domain scores.   
 
Paired samples Wilcoxon Signed-Rank tests were conducted to compare differences 
between participant total and domain ACE-III scores at session one and session two.  Table 
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3 presents the median, interquartile range, and test statistics.  The results indicated that there 
was not a statistically significant difference between participant total ACE-III scores at 
session one and session two.  There was a statistically significant different between 
participant scores on the fluency domain (Z = -2.309, p =.021) with a medium effect size.  
Small effect sizes that were not statistically significant were also observed for the memory, 
attention, language, and visuospatial domains.   
 
Table 3 Differences in participant total and domain ACE-III scores between session one and session two 
                                                                                                           Test statistics (N =37) 
 Mdn 
Session 
1 
Interquartile     
Range 
Mdn 
Session 
2 
Interquartile     
Range 
 
Z 
 
P 
 
r 
        
Attention  13 12 - 13 13 13 -13 -0.250 0.803 0.04 
Memory  17.5 16.25 - 18 17.5 17 - 18 -0.783 0.434   
0.13 
Fluency  4 4 -4 4  4 - 4 -2.309 0.021 0.37 
Language  22 21 - 22 22 21 - 22 -0.361 0.718 0.06 
Visuospatial  7 7 - 8 7  7 – 8  -0.968 0.333 0.16 
Total  63 62 – 64.75 63 62 - 64 -0.350 0.726 0.06 
 
 
Test-Retest Scoring Consistency  
 
The data indicates that 46% of participants were consistent in their scoring of the ACE-III 
total between session one and session two.  Only 13% of these participant scores matched 
the TS.  To verify the level of agreement between intra-rater ACE-III total and domain 
scores, the intraclass correlation coefficient (ICC) was used.  The ICC values were classified 
as follows: <0.4: poor reliability; 0.4-0.75: good reliability; >0.75: excellent reliability 
(Fleiss, Levin, & Paik, 2003).  A good level of intra-rater reliability was found for ACE-III 
total scores -  the ICC was .70 with a 95% confidence interval from .41 to .85 (F(35, 35) = 
3.300, p < .001.  Table 4 presents the ICC values for intra-rater total and domain scores.   
 
Table 4 Reliability of total and domain scores:  intraclass correlation coefficient (ICC) 
 ICC (95% CI) 
Attention                                                   .06 (-.91, .53) 
Memory  .49 (-.01, .74) 
Fluency  .29 (-.28, .62) 
Language  .56 (.13, .78) 
Visuospatial  .58 (.18, .79) 
Total  .70 (.41, .85) 
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Participant ACE-III Experience and Training  
 
A secondary exploratory analysis was conducted to examine whether scoring accuracy was 
affected by participants’ experience of using the ACE-III and/or whether they received 
training on how to administer and score it.  The majority of participants (66%) reported 
having used the ACE-III in clinical practice for 5 years or more, and 88% reported using it 
at least once a month.  Almost all of the participants (90%) reported having received some 
form of ACE-III training which consisted of either informal training (i.e. observing the 
practice of another clinician administering and scoring the ACE-III and then being observed 
administering and scoring the test themselves) or more formal training (i.e. through the NHS 
Education for Scotland (NES) online training programme).  During their participation in the 
study, only 44% of participants utilised the ACE-III scoring and administration guide.  
Analyses were completed to explore participants’ deviation from the TS between each of the 
following groups:   
 
(i) Participants who had received ACE-III training (n = 37) and those who had not 
(n = 3).  
(ii) Participants who utilised the ACE-III scoring and administration guide during 
their participation in the study (n = 18) and those who did not (n = 22). 
(iii) Participants who reported using the ACE-III in clinical practice frequently (i.e. 
between once a week to once a month) (n = 36) and those who reported using the 
ACE-III infrequently (i.e. between once every three months to less than once 
every six months) (n = 4).  
(iv) Participants who reported using the ACE-III in clinical practice for less than 5 
years (n = 13) and those who reported using the ACE-III for 5 years or more (n 
= 27).   
 
Independent-Samples Mann-Whitney U Tests were conducted to explore participants’ 
deviation from the TS for groups (ii) and (iv).  No significant differences in scoring 
performance were found.  Table 5 presents the median deviation from the true score, 
interquartile range, and test statistics.  Due to the very small number of participants for the 
sub-groups in (i) and (iii), only measures of central tendency are provided.  
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Table 5 Median deviation from the true score for participants based on training, whether the 
scoring guide was used, frequency of ACE III use, and length of time using the ACE III. 
                                                                                      Test Statistics  
  
Mdn 
 
Interquartile  
Range 
 
 
N 
 
U 
 
P 
Training  
Yes  1 1 - 3 37  
 
 
 No 3 2 - 3    3 
Scoring guide used  
Yes 1 1 – 2.25 18  
184.5 
 
0.706 No 2 0 - 3 22 
Frequency of use 
Once a week - Once a month 1 1 - 3 36  
 
 
 Once every 3 months –  
Less than once every 6 
months  
 
 
3.5 2.25 – 4.75 4 
Length of use  
Less than 5 years  1 0.5 – 1.5 13  
125.0 
 
0.134 
5 years or more  2 2 - 2 27 
 
 
Calculation Errors  
 
At session one, 10% (4/40) of participants made a calculation error while ‘summing up’ 
items to obtain an overall total score.    This meant that for these ACE-III forms, the total 
score recorded differed from the actual summed total of items.  Calculation errors did not 
exceed two points for any participant.  At session two, only 3% (1/37) of participants made 
a calculation error affecting the overall total ACE-III score. The calculation error here 
consisted of one point.   
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Discussion 
 
This study found that the inter- and intra-rater scoring accuracy of the ACE-III is generally 
good, with error mainly accounted for by the domains which require more subjective 
judgements, namely, the visuospatial and language tests.  The majority of participants’ 
scores on the ACE-III did not deviate from the TS by any more than 2 points at total, domain, 
and sub-domain levels.  This margin of error should be acceptable in clinical practice given 
that the ACE-III is a screening measure rather than a diagnostic tool, and scores should be 
interpreted accordingly.  However, if ‘cut off’ scores are adhered to rigidly, even small 
variations in scores could have significant clinical implications.  These findings are in 
keeping with a previous study examining the scoring accuracy of the ACE-III’s predecessor, 
the ACE-R, using similar methods (Crawford, 2010).   Also in relation to ACE-III total 
scores, there was a tendency towards over-scoring across both sessions. It could be possible 
that some health professionals give patients ‘the benefit of the doubt’ when scoring screening 
tools, which may account for this finding.  If patient performance on the ACE-III is over-
scored in clinical practice this could potentially lead to false negative results and 
compromise the accurate and early identification of those individuals with a dementia.   
 
The study also found that particular ACE-III domains were associated with less scoring 
accuracy, and highlighted the challenges of scoring where subjective judgements are 
required, as with the visuospatial and language tests.  The study found a statistically 
significant difference between participant scores and the TS on the visuospatial and language 
domains, with large effect sizes.  Deviation from the TS on these domains was mainly 
accounted for by scoring errors on the clock drawing item and the single word repetition 
item respectively, and this was observed across both sessions.  In relation to the clock 
drawing item, participants may not have been aware of the guidelines for assigning points 
according to the clock face, the inclusion and distribution of numbers, and the placement of 
the clock hands, as outlined in the ACE-III scoring guide.  The simulated older adult patient 
in the vignette did not perform very well on this test which may have increased the amount 
of subjectivity required in the process of scoring. The single word repetition item requires 
the patient to repeat several words correctly.  In the vignette, the simulated older adult patient 
pronounced one of the words incorrectly at the first attempt, and then correctly upon a second 
attempt.  It would seem that most of the participants gave this response full marks despite 
the scoring guide instructions stipulating that ‘only the first attempt is scored’.  This may 
indicate that some participants were not aware of the scoring instructions for this item.   
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Indeed, if individuals do not frequently refer to, and are not familiar with, the ACE-III 
administration and scoring guide, they may develop their own unique scoring methods.  To 
improve scoring accuracy within these subjective domains, it may be helpful to include more 
detailed guidance on acceptable responses for these items within the ACE-III administration 
and scoring guidelines.  That said, during their participation in the study, only 44% of 
participants utilised the ACE-III scoring and administration guide which may suggest that 
the guidelines are not routinely referred to in clinical practice.  An alternative way of 
reducing scoring errors, particularly within the domains where a greater degree of rater 
interpretation is required, may be to adapt ACE-III scoring forms to include more detailed 
scoring information for these items on the form.  Similar findings were highlighted by 
Crawford (2010) in relation to the ACE-R and, to address some of the issues, an online 
training programme was later developed by NES to help staff administer the newly 
developed ACE-III.  The online training programme provides NHS staff with the knowledge 
and skills to use the ACE-III, giving them the opportunity to become familiar with 
administering and scoring the tool prior to clinical experience or as a refresher for those who 
have not administered and scored it for a significant length of time (NES, 2019).  Indeed, 
perhaps the design of the current study could be adapted in future to examine the impact of 
viewing an instructional video on the ACE-III on scoring accuracy.   
 
As noted previously, there was slightly less deviation from the ACE-III total TS at session 
two in comparison to session one which may be accounted for by practice effects (i.e. recall 
effects), particularly given that there was a relatively short time period of two months 
between session one and session two.  The correlation coefficient obtained for participant 
ACE-III total scores between session one and two suggests that the ACE-III has a good level 
of test-retest consistency.  It should be noted however that test-retest consistency was lower 
for the sub-domains.   
 
The present study also examined whether scoring accuracy was affected by participants’ 
experience of using the ACE-III and/or whether they had received training on how to 
administer and score it, and found that neither led to statistically significant differences in 
scoring performance.  The majority of participants in the study had indeed received training 
on how to administer and score the ACE-III and most of the participants also had five or 
more years of experience using it therefore we may deduce from this that the ACE-III, even 
when used by appropriately skilled individuals, is still susceptible to some rater error.    
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These results should be interpreted with caution however given that the sub-groups of 
participants in these analyses had small numbers. 
 
Only a small number of participants made a calculation error whilst summing up the scores 
which suggests that participants took time and care over this.  Indeed, it was observed at the 
sessions that participants would double or even triple check that they had summed the total 
and domain scores accurately.  One participant did not sum items to provide domain and 
total scores however this only occurred at session one and is therefore likely to have been an 
oversight.   
 
Study Limitations  
 
The design of this study enabled scoring accuracy to be investigated separately from 
administration consistency through the use of a scripted vignette and pre-determined ACE-
III ‘true’ scores.  It is possible that the ‘true’ scores may not have been an accurate reflection 
of actual scores and this is a potential limitation of the study design.  The likelihood of this 
however is small given that the ‘true’ scores had been rated and agreed upon independently 
by two experienced Clinical Psychologists.  Another potential limitation of the study design 
relates to the inability of participants to seek clarification and/or ask the patient to repeat 
themselves if they did not hear the responses as would be possible in real life settings.  Some 
of the scoring errors made by participants, therefore, may have been due to their inability to 
hear the simulated older adult patient’s responses, and/or mishearing responses, on the 
vignette.  It should also be noted that while statistical significance is reported in the study 
when measuring difference between participants scores and predetermined ‘true’ scores, 
from a clinical perspective, this is of limited value as the question of how many points 
deviation from the ‘true’ score is clinically acceptable cannot be answered statistically.  The 
judgement made that a few points deviation is likely to be clinically acceptable is based upon 
expert opinion rather than statistical assessment.  In addition, all of the participants scores 
of the vignette correctly identified the patient as being in the impaired range.  Indeed, the 
ACE-III ‘true’ score was significantly below the cut-off required for a diagnosis of dementia.   
If the ‘true’ score had been closer to the cut-off,  that is, the point at which an individual’s 
score moves from being within the ‘normal’ range to being within the ‘impaired’ range, it 
may have enhanced our understanding of scoring accuracy when an individual’s presentation 
is less clear.  This is, after all, the main aim of a cognitive screening test in clinical practice.  
As such, this is another limitation of the current research.   A further limitation of the study 
relates to the test re-test method of assessing the scoring consistency of participants across 
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two different time points as there is potential for learning or recall effects.  The short time 
interval of two months between the two test administrations may make these carryover 
effects more likely.  To reduce these effects, a longer period of time between sessions would 
have been favourable.  Finally, although the overall sample size in the study exceeded the 
power calculation requirements, analysis involving sub-groups of participants had small 
numbers and therefore may have influenced the validity of results.    
 
 
Conclusion 
 
Given the widespread use of cognitive screening tests in the assessment of dementia, there 
has been surprisingly little research on their scoring accuracy in practical settings.  This 
study utilised a design which allowed for the scoring accuracy of the ACE-III to be explored 
independent of test administration.  Findings suggest that the inter- and intra-rater scoring 
accuracy of the ACE-III is generally good, with error mainly accounted for by the domains 
which require more subjective judgements.  Health professionals should therefore take these 
findings into account when scoring the ACE-III, and perhaps utilise the ACE-III 
administration and scoring guide to help improve accuracy.  It may also be helpful to adapt 
ACE-III scoring forms to include more detailed scoring information for the items where a 
greater degree of rater interpretation is required.  Health professionals may also wish to 
refresh their skills in administering and scoring the ACE-III through the NES online trainer 
programme.  Indeed, if all health professionals score the ACE-III in a consistent manner, the 
accurate and early identification and management of those individuals with a dementia will 
be improved.    
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Federal Policy for the Protection of Human Subjects; or European Medicines Agency 
Guidelines for Good Clinical Practice. It should also state clearly in the text that all persons 
gave their informed consent prior to their inclusion in the study. 
Patient anonymity should be preserved. Photographs need to be cropped sufficiently to 
prevent human subjects being recognized (or an eye bar should be used). Images and 
information from individual participants will only be published where the authors have obtained 
the individual's free prior informed consent. Authors do not need to provide a copy of the 
consent form to the publisher; however, in signing the author license to publish, authors are 
required to confirm that consent has been obtained. Wiley has a standard patient consent 
form available for use. 
Animal Studies 
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A statement indicating that the protocol and procedures employed were ethically reviewed and 
approved, and the name of the body giving approval, must be included in the Methods section 
of the manuscript. We encourage authors to adhere to animal research reporting standards, 
for example the ARRIVE reporting guidelines for reporting study design and statistical 
analysis; experimental procedures; experimental animals and housing and husbandry. Authors 
should also state whether experiments were performed in accordance with relevant 
institutional and national guidelines and regulations for the care and use of laboratory animals: 
• US authors should cite compliance with the US National Research Council's Guide for the 
Care and Use of Laboratory Animals, the US Public Health Service's Policy on Humane 
Care and Use of Laboratory Animals, and Guide for the Care and Use of Laboratory 
Animals. 
• UK authors should conform to UK legislation under the Animals (Scientific Procedures) 
Act 1986 Amendment Regulations (SI 2012/3039). 
• European authors outside the UK should conform to Directive 2010/63/EU. 
Clinical Trial Registration 
The journal requires that clinical trials are prospectively registered in a publicly accessible 
database and clinical trial registration numbers should be included in all papers that report 
their results. Authors are asked to include the name of the trial register and the clinical trial 
registration number at the end of the abstract. If the trial is not registered, or was registered 
retrospectively, the reasons for this should be explained. 
Research Reporting Guidelines 
Accurate and complete reporting enables readers to fully appraise research, replicate it, and 
use it. Authors are expected to adhere to recognised research reporting standards. The 
EQUATOR Network collects more than 370 reporting guidelines for many study types, 
including for: 
• Randomised trials: CONSORT 
• Observational studies: STROBE 
• Systematic reviews: PRISMA 
• Case reports: CARE 
• Qualitative research: SRQR 
• Diagnostic / prognostic studies: STARD 
• Quality improvement studies: SQUIRE 
• Economic evaluations: CHEERS 
• Animal pre-clinical studies: ARRIVE • Study protocols: SPIRIT 
• Clinical practice guidelines: AGREE 
We also encourage authors to refer to and follow guidelines from: 
• Future of Research Communications and e-Scholarship (FORCE11) 
• National Research Council's Institute for Laboratory Animal Research guidelines 
• The Gold Standard Publication Checklist from Hooijmans and colleagues 
• Minimum Information Guidelines from Diverse Bioscience Communities (MIBBI) 
website 
• FAIRsharing website 
Species Names 
Upon its first use in the title, abstract, and text, the common name of a species should be 
followed by the scientific name (genus, species, and authority) in parentheses. For well-known 
species, however, scientific names may be omitted from article titles. If no common name 
exists in English, only the scientific name should be used. 
Genetic Nomenclature 
Sequence variants should be described in the text and tables using both DNA and protein 
designations whenever appropriate. Sequence variant nomenclature must follow the current 
HGVS guidelines; see http://varnomen.hgvs.org/, where examples of acceptable 
nomenclature are provided. 
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Sequence Data 
Nucleotide sequence data can be submitted in electronic form to any of the three major 
collaborative databases: DDBJ, EMBL, or GenBank. It is only necessary to submit to one 
database as data are exchanged between DDBJ, EMBL, and GenBank on a daily basis. The 
suggested wording for referring to accession-number information is: ‘These sequence data 
have been submitted to the DDBJ/EMBL/GenBank databases under accession number 
U12345’. Addresses are as follows: 
• DNA Data Bank of Japan (DDBJ): http://www.ddbj.nig.ac.jp 
 
• EMBL Nucleotide Archive: ebi.ac.uk/ena 
• GenBank: www.ncbi.nlm.nih.gov/genbank 
Proteins sequence data should be submitted to either of the following repositories: 
• Protein Information Resource (PIR): pir.georgetown.edu 
• SWISS-PROT: expasy.ch/sprot/sprot-top 
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The journal requires that all authors disclose any potential sources of conflict of interest. Any 
interest or relationship, financial or otherwise that might be perceived as influencing an 
author's objectivity is considered a potential source of conflict of interest. These must be 
disclosed when directly relevant or directly related to the work that the authors describe in their 
manuscript. Potential sources of conflict of interest include, but are not limited to: patent or 
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Authors should list all funding sources in the Acknowledgments section. Authors are 
responsible for the accuracy of their funder designation. If in doubt, please check the Open 
Funder Registry for the correct nomenclature: https://www.crossref.org/services/funder-
registry/ 
Authorship 
The list of authors should accurately illustrate who contributed to the work and how. All those 
listed as authors should qualify for authorship according to the following criteria: 
1. Have made substantial contributions to conception and design, or acquisition of data, or 
analysis and interpretation of data; 
2. Been involved in drafting the manuscript or revising it critically for important intellectual 
content; 
3. Given final approval of the version to be published. Each author should have participated 
sufficiently in the work to take public responsibility for appropriate portions of the content; and 
4. Agreed to be accountable for all aspects of the work in ensuring that questions related to 
the accuracy or integrity of any part of the work are appropriately investigated and resolved. 
Contributions from anyone who does not meet the criteria for authorship should be listed, with 
permission from the contributor, in an Acknowledgments section (for example, to recognize 
contributions from people who provided technical help, collation of data, writing assistance, 
acquisition of funding, or a department chairperson who provided general support). Prior to 
submitting the article all authors should agree on the order in which their names will be listed 
in the manuscript. 
Additional Authorship Options. Joint first or senior authorship: In the case of joint first 
authorship, a footnote should be added to the author listing, e.g. ‘X and Y should be 
considered joint first author’ or ‘X and Y should be considered joint senior author.’ 
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This journal is a member of the Committee on Publication Ethics (COPE). Note this journal 
uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in 
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submitted manuscripts. Read Wiley’s Top 10 Publishing Ethics Tips for Authors here. Wiley’s 
Publication Ethics Guidelines can be found here. 
ORCID 
As part of the journal’s commitment to supporting authors at every step of the publishing 
process, the journal encourages the submitting author (only) to provide an ORCID iD when 
submitting a manuscript. This takes around 2 minutes to complete. Find more information 
here. 
6. AUTHOR LICENSING 
If a paper is accepted for publication, the author identified as the formal corresponding author 
will receive an email prompting them to log in to Author Services, where via the Wiley Author 
Licensing Service (WALS) they will be required to complete a copyright license agreement on 
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Authors may choose to publish under the terms of the journal’s standard copyright agreement, 
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Appendix 1.3 Quality assessment scores for each included paper  
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Appendix 2.1 Participant Information Sheet  
 
                                                                                         
 
 
 
Institute of Health and Wellbeing  
College of Medical, Veterinary and Life Sciences                                        
University of Glasgow 
Administration Building   
Gartnavel Royal Hospital 
1055 Great Western Road 
Glasgow  
G12 0XH  
 
An Investigation into the Reliability of the Addenbrooke’s Cognitive 
Examination-III (ACE-III) 
Information Sheet 
 
I would like to invite you to take part in a research study.  Before you decide whether or not 
you wish to take part, it is important for you to understand why the research is being done 
and what it would involve for you.  Please take time to read the following information 
carefully.  If there is anything that is not clear or if you would like more information, please 
contact me.    
 
Who is conducting the research? 
 
The research is being carried out by Hollie Thomson (Trainee Clinical Psychologist) from 
the Institute of Health and Wellbeing at the University of Glasgow.   
 
What is the purpose of the study? 
 
The study aims to explore how a clinical presentation is scored on the Addenbrooke’s 
Cognitive Examination-III (ACE-III) by professionals working within the NHS.   
 
Why have I been invited? 
 
You have been invited to take part in this study because you have had experience 
administering and scoring the Addenbrooke’s Cognitive Examination-III (ACE-III) 
clinically.   
 
Do I have to take part? 
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No. Taking part in this research is entirely voluntary.  It is up to you to decide whether or 
not you wish to take part.  If you do decide to take part, you will be given a copy of this 
information sheet to keep and asked to sign a consent form to show that you have agreed to 
take part.  You are free to withdraw at any time, without giving a reason.   
 
 
What does taking part involve? 
 
Taking part involves attending two sessions.  The study will be conducted in meeting or 
lecture rooms at the University of Glasgow premises, or within NHS settings. At session 
one, you will be shown a vignette of an older adult actor being administered the ACE-III.  
You will be required to watch the vignette in its entirety whilst concurrently scoring an 
accompanying ACE-III form.  You will also be asked to complete an additional information 
sheet detailing your occupation and your experience to date using the ACE-III as well as any 
formal training you have completed on the ACE-III.  Session two will take place 
approximately two months after session one.  At session two, you will again be asked to 
watch a vignette of an older adult actor being administered the ACE-III and again asked to 
score an accompanying ACE-III form.  It is anticipated that each session should last no more 
than one hour.   
 
What happens to the information? 
Your identity and personal information will be completely confidential and seen only by 
researchers and regulators whose job it is to check the work of researchers.  The information 
obtained will remain confidential and stored in a locked filing cabinet within the University 
of Glasgow premises and/or electronically on a password protected computer.  The data is 
held in accordance with the Data Protection Act (2018), which means that it is kept safely 
and cannot be revealed to other people without your permission.  The data will be stored in 
archiving facilities for up to 10 years in accordance with relevant Data Protection policies 
and regulations.  After this period, further retention may be agreed or your data will be 
securely destroyed in accordance with the relevant standard procedures.  The results of the 
study will be disseminated via email to the Community Mental Health Team's from which 
staff participated.  Planned dissemination also includes completion of a DClinPsy thesis, 
publication in a scientific journal, and presentation at a scientific conference.   
What are the possible benefits of taking part? 
 
It is hoped that by taking part in this research, you will be providing valuable information 
regarding how professionals score the ACE-III in clinical situations.  It is hoped that this 
information will influence further research into how dementia screening tools are utilised by 
clinicians.   
 
Who has reviewed the study? 
 
This study has been reviewed by the University of Glasgow College of Medical, Veterinary 
and life Sciences (MVLS) Ethics Committee and the NHS Greater Glasgow and Clyde 
(GG&C) Research and Development Department. 
 
If you have any further questions? 
 
If you would like further information about this research project please contact the 
researcher, Hollie Thomson, or alternatively her academic supervisor Prof. Jonathan Evans, 
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or her clinical supervisor, Dr. Stephanie Crawford. If you wish to seek general advice about 
participating in this study from someone not closely linked to the study, please contact Prof. 
Tom McMillan. Please find all contact details below.   
 
 
Miss Hollie Thomson  
Trainee Clinical Psychologist 
Institute of Health and Wellbeing  
College of Medical, Veterinary and Life Sciences  
University of Glasgow 
Administration Building   
Gartnavel Royal Hospital 
1055 Great Western Road 
Glasgow  
G12 0XH  
Tel: 0141 211 0607 
Email: Hollie.Thomson@ggc.scot.nhs.uk  
 
Professor Jonathan Evans  
Professor of Applied Neuropsychology  
Institute of Health and Wellbeing  
College of Medical, Veterinary and Life Sciences  
University of Glasgow 
Administration Building   
Gartnavel Royal Hospital 
1055 Great Western Road 
Glasgow  
G12 0XH  
Tel: 0141 211 0694 
Email:  Jonathan.Evans@glasgow.ac.uk  
Dr. Stephanie Crawford 
Consultant Clinical Psychologist 
Inverclyde Older People CMHT 
Crown House 
30 King Street 
Greenock 
PA15 1NL 
Tel: 01475 558045 
Email: Stephanie.Crawford@ggc.scot.nhs.uk  
Professor Tom McMillan  
Professor of Clinical Neuropsychology                                                      
Institute of Health and Wellbeing  
College of Medical, Veterinary and Life Sciences  
University of Glasgow 
Administration Building   
Gartnavel Royal Hospital 
1055 Great Western Road 
Glasgow  
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G12 0XH  
Tel: 0141 211  0354      
Email:  Thomas.McMillan@glasgow.ac.uk           
If you have a complaint about any aspect of the study? 
 
If you are unhappy about any aspect of the study and wish to make a complaint, please 
contact the researcher in the first instance. The normal NHS complaint mechanisms are 
also available to you.  The contact details are as follows: 
 
Complaints Department 
West Glasgow Ambulatory Care Hospital 
Dalnair Street 
Glasgow 
G3 8SJ 
Phone: 0141 201 4500 
Email: complaints@ggc.scot.nhs.uk 
 
Thank you for your time.   
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Appendix 2.2 Additional Information Sheet  
Institute of  Health and Wellbeing                                                        
College of Medical, Veterinary and Life Sciences  
University of Glasgow 
Administration Building   
Gartnavel Royal Hospital 
1055 Great Western Road 
Glasgow  
G12 0XH  
 
An Investigation into the Reliability of the Addenbrooke’s Cognitive 
Examination-III (ACE-III) 
Additional Information Sheet 
 
Please answer the following questions. 
 
1.  What is your occupation and how long have you been in this post? 
 
 
  
 
2. How often do you use the Addenbrooke’s Cognitive Examination-III (ACE-III) in 
your clinical work?  (Please circle the most appropriate response).   
 
Once a week                             Once a fortnight                              Once a month      
 
 
Once every 3 months              Once every 6 months           Less than once every 6 
months  
 
 
3.  (a) Have you participated in ACE-III training?  (Please circle).   
 
                      Yes                         No  
 
 
(b) If you answered ‘No’ to question 3(a) please state briefly how you learned to use 
the ACE-III. 
 
 
 
4.  Please give an estimate of how long you have used the ACE-III in your clinical 
practice: 
 
___________years and ___________months  
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Appendix 2.3 Participant Instructions  
An Investigation into the Reliability of the Addenbrooke’s Cognitive Examination-III 
(ACE-III) 
 
Participant Instructions 
 
 
 
Having read the information sheet, does anyone have any questions? 
 
If you are happy to proceed and participate in this study could you please complete the 
consent form and the additional information sheets that are in your research packs.  During 
the study you will be shown a vignette whereby the ACE-III is administered to a mock 
patient.  The vignette will be shown in its entirety only once; you have to score each section 
of the ACE-III as you watch the vignette as though you are the one administering it.  There 
should be no conferring throughout the study.  There will be time to total up each of the 
sections at the end.  A scoring guide is available on request should you wish to refer to it 
when scoring up at the end.  In your pack, there is a sheet that provides the correct answers 
for the orientation section of the ACE-III for this vignette; please refer to this when scoring 
this section.   
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Appendix 2.4 Vignette Orientation Information  
An Investigation into the Reliability of the Addenbrooke’s Cognitive Examination-III 
(ACE-III) 
 
Orientation Information 
 
 
 
ACE-III:  English Version A 
 
Day: Thursday,  
Date: 7th  
Month:  March  
Year: 2013 
Season:  Spring 
Floor:  4th  
Hospital: Glasgow Royal Infirmary Hospital 
Town:  Glasgow 
County:  City of Glasgow 
Country: Scotland 
Current Prime Minister: David Cameron 
Current President: Barack Obama  
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Appendix 2.5 Participant Consent Form  
                                                                                   
Institute of Health and Wellbeing           
College of Medical, Veterinary and Life Sciences  
University of Glasgow 
Administration Building   
Gartnavel Royal Hospital 
1055 Great Western Road 
Glasgow  
G12 0XH  
An Investigation into the Reliability of the Addenbrooke’s Cognitive 
Examination-III (ACE-III) 
Consent Form 
 
 
Please initial box 
 
I confirm that I have read and understood the Participant      
Information Sheet version 1, dated 01/02/2019.   
I confirm that I have read and understood the Privacy Notice 
version 1, dated 01/02/2019.   
I have had the opportunity to think about the information and ask 
questions, and understand the answers I have been given.  
I understand that my participation is voluntary and that I am free 
to withdraw at any time, without giving any reason, without my 
legal rights being affected. 
I confirm that I agree to the way my data will be collected and 
processed and that data will be stored for up to ten years in 
accordance with relevant Data Protection policies and regulations.  
I understand that all data and information I provide will be kept 
confidential and will be seen only by study researchers and 
regulators whose job it is to check the work of researchers.  
I agree to take part in the study.  
________________                           ______________            ______________________ 
Name of Participant (PRINT)              Date                                Signature 
 
_________________                           ______________            ______________________ 
Name of Researcher (PRINT)              Date                                 Signature  
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Appendix 2.6  MVLS College Ethics Committee Approval Letter  
 
 
 
 
Dear Professor Jonathan Evans 
 
MVLS College Ethics Committee 
Project Title: An Investigation into the Reliability of the Addenbrookes Cognitive 
Examination-III (ACE-III) 
 
Project No:  200180141 
 
The College Ethics Committee has reviewed your application and has agreed that 
there is no objection on ethical grounds to the proposed study.  We are happy 
therefore to approve the project, subject to the following conditions. 
 
• Project end date as stipulated in original application. 
   
• The data should be held securely for a period of ten years after the completion of the 
research project, or for longer if specified by the research funder or sponsor, in 
accordance with the University’s Code of Good Practice in Research: 
(http://www.gla.ac.uk/media/media_227599_en.pdf)   
 
• The research should be carried out only on the sites, and/or groups defined in the 
application. 
 
• Any proposed changes in the protocol should be submitted for reassessment, except 
when it is necessary to change the protocol to eliminate hazard to the subjects or where 
the change involves only the administrative aspects of the project. The Ethics 
Committee should be informed of any such changes. 
 
• For projects requiring the use of an online questionnaire, the University has an Online 
Surveys account for research. To request access, see the University’s application 
procedure at 
https://www.gla.ac.uk/research/strategy/ourpolicies/useofonlinesurveystoolforresearch
/. 
 
• You should submit a short end of study report to the Ethics Committee within 3 months 
of completion. 
 
• Permissions from clinical leads will also be required for this study of NHS staff. 
 
Yours sincerely 
 
 
 
Dr Terry Quinn 
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Abstract 
 
Background:  Dementia is a leading cause of disability amongst older adults in the 
developed world.   In recent years, an increasing emphasis has been placed on the early 
detection and diagnosis of dementia, and timely access to post-diagnostic support.  Cognitive 
screening tests are essential tools in facilitating the process of early detection and dementia 
diagnosis and are currently widely used in clinical practice.    The Addenbrooke’s Cognitive 
Examination-III (ACE-III) is one such tool; a cognitive screening test commonly used in the 
assessment of dementia.  Despite it being recommended in several evidence-based 
guidelines and being widely used in the NHS, the rater reliability of the ACE-III has never 
been formally evaluated. Aims:  To investigate rater accuracy in scoring the ACE-III both 
in terms of its total and sub-category scores across different raters and by the same raters at 
two different time points.  A secondary exploratory analysis examines whether scoring 
accuracy is affected by participants’ experience of using the ACE-III and/or whether they 
have had formal training on how to administer and score the ACE-III.  Methods:  A filmed 
vignette of the ACE-III being administered to an older adult actor (mock patient) will be 
used to assess scoring accuracy across different raters.  The vignette has a pre-determined 
‘true’ score.  Participants will be asked to view the filmed vignette whilst simultaneously 
completing an ACE-III scoring sheet.   Following a two-month period, participants will be 
invited back to view and score the same vignette again to assess intra-rater reliability.  
Participants will be NHS staff working in Older People’s Community Mental Health Teams 
and Memory Assessment Centres who routinely administer and score the ACE-III as part of 
their clinical practice.  Applications:  This study addresses a gap in the literature by 
providing information on the rater reliability of the ACE-III.  Given that the ACE-III is a 
screening test commonly used in the assessment of dementia and has the potential to 
facilitate the early identification and management of those individuals with a dementia, 
establishing its reliability is a highly clinically relevant area for research.   
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Introduction 
 
Background  
 
Dementia is an umbrella term for a range of progressive conditions that are characterised by 
global impairment of cognitive functioning (Alzheimer’s Society, 2018).  Dementia is a 
leading cause of disability amongst older adults in the developed world, and constitutes one 
of the most significant, and costly, challenges currently facing health and social care services 
(Milne et al., 2008).  In the UK alone, there are approximately 850,000 people currently 
living with a dementia (Alzheimer’s Society, 2018).  Given that age is the biggest risk factor 
for developing a dementia, and that the average life expectancy is increasing, it is not 
surprising that the incidence and prevalence of dementia is expected to rise rapidly over the 
next several decades.  Indeed, it is estimated that by 2051 there will be around two million 
people in the UK living with a dementia (Alzheimer’s Society, 2018).  Over the past decade, 
the Scottish Government has made dementia a public health priority and has set out a range 
of commitments and objectives to improve the quality of care for individuals with a 
dementia, with increasing emphasis being placed on early detection and diagnosis, and 
timely access to post-diagnostic support (Scottish Government, 2017).  Early detection of 
dementia is essential to ensuring early intervention and management of the condition, and 
improving the individuals’ quality of life. (Scottish Government, 2017).     
 
The Role of cognitive screening tests in dementia diagnosis  
 
The National Institute for Health and Care Excellence (NICE, 2018) has recently published 
up to date guidelines on the diagnosis and management of dementia which stipulate the use 
of a validated brief structured cognitive screening test as part of the initial stage of a 
comprehensive dementia assessment. Indeed, the assessment of cognitive functioning is 
central to the process of early detection and diagnosis of dementia and is therefore arguably 
one of the most important assessments made by clinicians in clinical practice (Machado et 
al., 2015).  In the context of time constraints, the efficient early detection of dementia 
requires the use of an objective cognitive screening test which is brief, reliable, easy to 
administer, and acceptable to patients (Cullen et al., 2007; Villarejo & Puerta-Martin, 2011).   
It is not surprising then that in recent years there has been an increase in the number of 
dementia screening tests proposed and studied.    
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The main aim of a cognitive screening test is to provide information about the presence, or 
absence, of a cognitive impairment (Lezak et al., 2004).  This is often inferred from the 
individuals’ score on the test compared to referenced norms (Cullen et al., 2007).  A central 
feature of most screening tests is the ‘cut off’ score, that is, the point at which an individual’s 
score moves from being within the ‘normal’ range to being within the ‘impaired’ range, i.e. 
indicating the presence of a dementia.  The success of a screening test in achieving this aim 
undoubtedly lies in its psychometric robustness (Cullen et al., 2007).  Cognitive screening 
tests should have good sensitivity and specificity to ensure that individuals with a cognitive 
impairment are not missed and that individuals without a cognitive impairment are not 
misidentified as impaired and referred on for further testing unnecessarily (Stolwyk et al., 
2014).   
 
One of the most important attributes of any assessment instrument is its reliability, that is, 
the extent to which the test produces consistent measurements when repeated under replicate 
conditions (Van Belle & Arnold, 2000).  There are a number of factors which may influence 
the reliability of a test including individual factors (i.e. mood, fatigue, and motivation), 
environmental factors (i.e. temperature and noise), and rater factors (i.e. training, experience, 
judgement).  These factors are sources of measurement error in the assessment process.   If 
these measurement errors did not exist, one would expect that an individual would obtain 
the same test score, their ‘true’ score, each time they took the test.  It is generally accepted 
however that the observed score on a test equates to the ‘true’ score plus some degree of 
measurement error (Trochim, 2006).  Thus, the extent to which a cognitive test can minimise 
the impact of measurement errors, and ensure that the score obtained is as close to the 
individuals ‘true’ score as possible, is an indication of its reliability (Trochim, 2006).  Inter-
rater reliability is the level of scoring consistency between raters evaluating the same test.   
High levels of agreement between raters is thought to be indicative of high inter-rater 
reliability.  However, agreement between raters does not necessarily equate to scoring 
accuracy when evaluating a test, since raters may show high levels of agreement but show 
low levels of accuracy.  Therefore, rater accuracy in scoring tests across different raters is 
an important aspect of reliability that must be taken into consideration in inter-rater 
reliability studies.  Intra-rater reliability assesses scoring consistency by the same raters at 
two different time points.  High levels of scoring consistency by raters at two different time 
points, indicates high levels of intra-rater reliability.    
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The ACE-III as a cognitive screening test for dementia 
The Addenbrooke’s Cognitive Examination, which is now in its third edition (ACE-III), is 
one of the cognitive screening tests recommended by the Scottish Intercollegiate Guideline 
Network (SIGN) in its guideline on the Management of Patients with Dementia (SIGN, 
2006).  The ACE-III is comprised of five subscales, each representing a cognitive domain; 
Attention, Memory, Fluency, Language, and Visuo-spatial.  A maximum score of 100 can 
be obtained, with higher scores indicative of better memory and cognitive performance.   The 
ACE-III is designed to be sensitive to the early stages of dementia, and has been shown to 
compare favourably with its predecessor, the ACE- R, with similar levels of sensitivity and 
specificity in the assessment of cognitive deficits in people with Alzheimer’s disease and 
fronto-temporal dementia (Hsieh et al., 2013). The ACE-III continues to show high 
sensitivity and specificity for dementia at cut offs previously recommended, i.e. 88 
(sensitivity = 1.0; specificity = 0.96) and 82 (sensitivity = 0.93; specificity = 1.0). It takes 
approximately 15 minutes to administer the ACE-III and it therefore meets the requirements 
of a screening test which is time efficient (Cullen et al., 2007).  There are three versions of 
the ACE-III available to reduce any practice effects with repeat testing.  Appropriate use of 
the ACE-III requires clinicians who are able to accurately administer, score, and interpret 
the test.   
The current study  
Although the psychometric properties of cognitive screening tests are widely reported, there 
is a dearth of research exploring the rater reliability and scoring accuracy of such tests among 
clinicians who routinely use them in clinical practice (Newman et al., 2018).  Previous 
studies examining test scoring on cognitive screening measures have found high rates of 
error (Crawford, 2010; Kozora, 2018; Sullivan, 2000) which highlights the importance of 
usability research, and ensuring that tests are used appropriately in real-world settings.  
Similarly, the consistency with which a test is scored by a range of clinicians is rarely 
reported.  This is particularly relevant when there are items on a test which require more 
subjective scoring judgments.       
 
Despite being recommended in several evidence-based guidelines as a screening test for 
dementia, and being widely used in the NHS, the rater reliability of the ACE-III has never 
been formally evaluated.  As with any method of objective testing, it is essential to establish 
whether the ACE-III is accurately and consistently scored across different raters and by the 
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same raters at different time points.  Indeed, this is highly relevant to ensuring the accurate 
and early identification and management of those individuals with a dementia.  Since the 
clinical utility of a test is limited without consideration of reliability, this is a highly clinically 
relevant area for research.   
 
Aims 
 
This study aims to investigate rater accuracy in scoring the ACE-III.  It will explore how 
accurately the ACE-III is scored both in terms of its total and sub-category scores across 
different raters and by the same raters at two different time points.    It will also consider 
whether scoring accuracy is affected by participants’ experience of using the ACE-III and/or 
whether they have had formal training on how to administer and score the ACE-III.  
 
Research Questions 
 
The specific research questions in relation to this study are: 
(i) Do participants’ ACE III total scores differ significantly from the ACE III ‘true’ 
score? 
(ii)  Do participants’ ACE-III sub-category scores differ significantly from the ACE-III 
‘true’ scores? 
(iii)  What is the test-retest scoring consistency across two different time points?   
 
Secondary Exploratory Analysis 
 
A secondary exploratory analysis will be conducted to examine whether scoring accuracy is 
affected by participants’ experience of using the ACE-III and/or whether they have had 
formal training on how to administer and score the ACE-III.  
 
Method 
 
Participants  
 
The participants in this study will be NHS staff working in Older People’s Community 
Mental Health Teams and Memory Assessment Centres in Greater Glasgow and Clyde and 
Dudley and Walsall Mental Health Partnership Trust who routinely administer and score the 
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ACE-III as part of their clinical practice.  To be considered eligible for inclusion in this 
study, participants are required to have administered and scored the ACE-III independently 
in clinical practice on at least one occasion with an older adult patient.  Some participants 
may have received formal training on how to administer and score the ACE-III.    
 
Justification of Sample Size  
 
The power calculation was based on the primary method of data analysis; a one sample t-
test.  In a similar study examining the rater reliability of the Addenbrooke’s Cognitive 
Examination-Revised (ACE-R), Crawford (2010) reported medium effect sizes.  A medium 
effect size is deemed to be sufficient enough to detect a clinically significant difference, that 
is, a difference large enough to alter interpretation of the ACE-III results.  G*Power (Faul et 
al., 2007) indicated that a minimum of 34 participants would be required to detect a medium 
effect size, with p=0.05, and a power of 0.8.   
 
Measures  
 
The Addenbrooke's Cognitive Examination-III (ACE-III) is the primary outcome measure.  
 
Design Procedure 
 
Permission was given to use a filmed vignette from the online NHS Education for Scotland 
(NES) ACE-III Trainer programme for the purposes of this study.  The University of 
Glasgow media services originally filmed and produced the vignette.  The vignette is of a 
Clinical Psychologist administering the ACE-III to an older adult actor (mock patient).  The 
vignette has pre-determined ‘true’ scores which had been rated, and agreed upon, by two 
experienced Clinical Psychologists.  Pre-determined ‘true’ scores allows for scoring 
consistency to be investigated separately from administration consistency.  A script for the 
vignette was developed by an advisory group of Clinical Psychologists with extensive 
neuropsychological experience within older adult services.  The vignette has a ‘true’ total 
score of 63/100.  
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Research Procedure 
 
Participants will be recruited from Older People’s Community Mental Health Teams across 
NHS Greater Glasgow and Clyde.  Potential participants will be invited to take part in the 
study via email.  Participants who are interested in taking part will receive an information 
sheet about the study (Appendix 1.1) and a consent form (Appendix 1.2).  Written consent 
will be obtained from all participants prior to the commencement of the study.  Participants 
who opt in to the study will then be invited to a group session lasting approximately one 
hour, where they will watch a vignette whilst simultaneously completing an ACE-III scoring 
sheet.  The vignette will be shown to participants in groups and played on a projector screen. 
Participants will be asked to view the vignette once and will not be permitted to pause or 
rewind it, reflecting actual clinical practice.  The ACE-III administration and scoring guide 
will be made available to participants on request.  Participants will not be permitted to 
consult each other regarding scoring and will be blinded from each other’s ratings.  
Participants will also be asked not to discuss their scoring after the session.  In addition to 
scoring the vignettes, participants will also be asked to complete an information form 
detailing their profession, ACE-III experience, and whether or not they have completed any 
formal training in using the ACE-III (Appendix 1.3).  A standardised set of instructions will 
be given verbally to each group of participants prior to commencing the study (Appendix 
1.4).  Participants will also be given the correct orientation information for the vignette 
(Appendix 1.5).  To evaluate intra-rater reliability, participants will be invited back after a 
period of approximately two months to view and score the same vignette again, under the 
same conditions and in an identical manner to the first time point.  Participants will be 
blinded from their previous ratings.  Participants will also be asked for an update as to 
whether they have received any additional ACE-III training since the previous test session.    
 
Settings and Equipment 
 
The study will be conducted in meeting or lecture rooms at the University of Glasgow 
premises, or within NHS settings.  A laptop and projector will be required to allow 
participants to view the vignette.  ACE-III scoring sheets, administration and scoring guides, 
and additional information sheets will also be required for each participant.    
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Data Analysis  
 
Descriptive statistics will be presented.  Proportions and standard deviations will be used to 
analyse the variation of test scores from the ‘true’ scores. Percentages will also be used to 
determine how many participants correctly identified the ‘true’ total and sub-test scores.  
Analysis will involve one sample t-tests to compare whether the participants’ ACE-III total 
scores differed significantly from the predetermined ACE-III ‘true’ scores, and to investigate 
whether the results obtained differ significantly from the ‘true’ sub-test scores.  Correlational 
methods will be used to explore intra-rater reliability, that is, whether participants’ ACE-III 
scores are consistent across two different time points.  Correlational methods will also be 
used to explore whether scoring accuracy is affected by participants’ experience of using the 
ACE-III and/or whether they have had formal training on how to administer and score the 
ACE-III.  Statistical analyses will be carried out using SPSS.        
 
Ethical Considerations 
 
Prior to commencement of the study, ethical approval will be sought from the College of 
Medical, Veterinary, and Life Sciences (MVLS) Ethics Committee.  Approval will also be 
sought from the NHS Greater Glasgow and Clyde Research and Development (R&D) 
Management Service, and the Dudley and Walsall Health Research Authority (HRA).  
Practice will be informed by the British psychological Society Code of Ethics and Conduct 
(2018).  Participants will be provided with information about the study prior to their 
participation to facilitate the process of informed consent.  Participants will be required to 
give informed consent prior to their participation.  Following participation in the study, 
participants will be informed about how the data will be used and reminded that individual 
results will not be revealed.   All of the data gathered for the purposes of the study will 
remain confidential and will be stored securely in accordance with the General Data 
Protection Regulations (GDPR).  It is not anticipated that the study will cause distress to 
participants.    
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Health and Safety Issues 
 
Researcher and Participant Safety Issues 
 
No significant health and safety issues are anticipated. Participants will be NHS staff and 
the study will be conducted at the University of Glasgow premises, or within NHS settings. 
 
Financial Issues 
 
No significant financial costs are expected.   
 
Practical Applications 
 
This study addresses a gap in the literature by providing information on the rater reliability 
of the ACE-III.   
 
Timetable 
 
Draft Proposal                                                                                            29th June 2018  
Final Proposal                                                                                   28th September 2018 
Obtain Ethical Approval                                                                           by March 2019  
Data Collection                                                                          April to September 2019  
Data Analysis and Write up                                                    October to December 2020 
Submission                                                                                          28th February 2020  
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